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For the constellation of neurological disorders known as chemotherapy induced 
neuropathy, mechanistic understanding, and treatment remain deficient.  In project one, 
I leveraged a multi-scale experimental approach to provide the first evidence that chronic 
sensory neuropathy depends on non-linear interactions between cancer and 
chemotherapy.  Global transcriptional profiling of dorsal root ganglia revealed amplified 
differential expression, notably in regulators of neuronal excitability, metabolism and 
inflammatory responses, all of which were unpredictable from effects observed with 
either chemotherapy or cancer alone.  Systemic interactions between cancer and 
chemotherapy also determined the extent of deficits in sensory encoding in vivo and ion 
channel protein expression by single mechanosensory neurons, with the potassium ion 
channel Kv3.3 emerging as candidate mechanisms explaining sensory neuron 
dysfunction. The sufficiency of this novel molecular mechanism was tested in an in 
silico biophysical model of mechanosensory function. Finally, validated measures of 
sensorimotor behavior in awake behaving animals confirmed that dysfunction after 
chronic chemotherapy treatment is exacerbated by cancer. Notably, errors in precise 
fore-limb placement emerged as a novel behavioral deficit unpredicted by our previous 
study of chemotherapy alone. These original findings identify novel contributors to 
peripheral neuropathy, and emphasize the fundamental dependence of neuropathy on 
the systemic interaction between chemotherapy and cancer across multiple levels of 
biological control.  
In project two, I extend study to multiple classes of mechanosensory neurons that are 
necessary for generating the information content (population code) needed for 
proprioception. I first tested the hypothesis that exacerbated neuronal dysfunction is 
conserved across multiple classes of mechanosensory neurons. Results revealed co-
 xiv 
suppression of specific signaling parameters across all neuronal classes. To understand 
the consequences of corrupt population code, I employed a long-short-term memory 
neural network (LSTM), a deep-learning algorithm, to test how decoding of 
spatiotemporal features of movement are altered after chemotherapy treatment of 
cancer. Results indicate that spiking activity from the population of neurons in animals 
with cancer, treated by chemotherapy contain significantly less information about key 
features of movement including, e.g. timing, magnitudes, and velocity. I then modeled 
the central nervous systems (CNS) capacity to compensate for this information loss. 
Even under optimal learning conditions, the inability to fully restore predictive 
power suggests that the CNS would not be able to compensate and restore full 
function. Our results support our proposal that lasting deficits in mobility and perception 
experienced by cancer survivors can originate from sensory information that is corrupted 
and un-interpretable by CNS neurons or networks.  
Collectively, I present the first evidence that chronic cancer neuropathy cannot be 
explained by the effects of chemotherapy alone but instead depend on non-linear 
interactions with cancer. This understanding is a prerequisite for designing future studies 
and for developing effective treatments or preventative measures.  
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CHAPTER 1. INTRODUCTION 
 
Societal Burden of Cancer   
Cancer diagnoses represent an ever-increasing burden on global society which is 
expected to grow to over 20 million new cases annually by 2025 (Ferlay, Soerjomataram 
et al. 2015).  While the incidence of cancer diagnoses expands (Center, Jemal et al. 
2009), increased screening and advanced treatment strategies, such as chemotherapies 
are extending disease-free lifespans (André, Boni et al. 2004; Edwards, Ward et al. 
2010; Bosetti, Levi et al. 2011; Avan, Postma et al. 2015).  
Chemotherapy’s Benefit to Survival 
One such example, platinum-based chemotherapies, are central pillars of contemporary 
cancer treatment.  Oxaliplatin (OX), a third-generation platinum-based agent, has been 
shown to extend lifespans by improving disease free survival up to 80%, reduce toxicity 
and improve tolerability, especially for older patients (Galanski, Jakupec et al. 2005; 
Montagnani, Turrisi et al. 2011; Johnstone, Park et al. 2014).  This superior efficacy as a 
first-line treatment for the 1.4 million new diagnoses of colorectal cancer (Torre, Bray et 
al. 2015) and adjunctive therapy for millions of bladder, ovarian and testicular cancers 
patients (Andre et al 2009; de Gramont, Et al 2000; Taylor et al 2014; Fu et al 2006) 
helps explain why it is estimated that approximately 50% of all patients diagnosed with 
cancer undergoing chemotherapeutic treatment receive a platinum-based chemotherapy 
such as OX (Galanski, Jakupec et al. 2005; (Johnstone, Park et al. 2014). 
Dark side of chemotherapy 
Despite impressive efficacy, nearly all patients treated with OX and other platinum-based 
drugs are afflicted by severe off-target, neurotoxic side-effects such as pain, sensory 
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abnormalities, fatigue, mobility and balance deficits (Bennett, Park et al. 2012).  This 
constellation dose-limiting side effects is collectively referred to as Chemotherapy-
Induced Peripheral Neuropathy (CIPN), diminishes quality of life and limits functional 
capacity (Cavaletti, Bogliun et al. 1995; Quasthoff and Hartung 2002; André, Boni et al. 
2004; Argyriou, Polychronopoulos et al. 2008; Alcindor and Beauger 2011; Mols, Beijers 
et al. 2013; Tofthagen, Donovan et al. 2013; Argyriou, Kyritsis et al. 2014; Beijers, Mols 
et al. 2014; Avan, Postma et al. 2015).  While, acute CIPN symptoms may decline after 
caseation of treatment, they frequently persist, leaving many patients with chronic CIPN 
that does not improve even years after treatment (Dietrich, Han et al. 2006; Park, Lin et 
al. 2011; Park, Goldstein et al. 2013; Aaronson, Mattioli et al. 2014; Seretny, Currie et al. 
2014; Marshall, Zipp et al. 2017). 
Seeking Treatments for CIPN 
Various approaches to prevent acute and ameliorate chronic CIPN have been attempted 
(Adelsberger, Quasthoff et al. 2000; Webster, Brain et al. 2005; Ishibashi, Okada et al. 
2010; Saif, Syrigos et al. 2010; Sittl, Lampert et al. 2012; Kagiava, K Kosmidis et al. 
2013).  However, these approaches have yet to show efficacy in large randomized 
control trials, leaving cancer patients’ symptoms essentially unabated (Loprinzi, Qin et 
al. 2013; Hershman, Lacchetti et al. 2014; Sisignano, Baron et al. 2014).  Given the lack 
of supporting evidence, The American Society of Clinical Oncologists recently published 
clinical practice guidelines that concluded, few, if any, therapeutic strategies are 
recommended (Hershman, Lacchetti et al. 2014). 
Knowledge gaps and motivations 
Abject failure of these clinical trials to lessen symptoms of CIPN present prima fascia 
evidence of knowledge gaps (Hershman, Lacchetti et al. 2014), promulgated by 
problems with preclinical study we correct in this work, notably 1) focus on transient 
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(acute) CIPN signs and symptoms at the expense of understanding lasting chronic 
effects, 2) flawed experimental methodologies, and 3) failure to consider role of cancer 
in pathophysiology of CIPN.   
Focus on Acute CIPN 
While it is clear that platinum-based drugs have the potential to disrupt neuronal 
excitability (Sittl, Lampert et al. 2012), the majority of studies have focused on 
elucidating underlying mechanisms of acute CIPN symptomology that do not persist, e.g. 
cold-induced pain, muscle spasms and cramps (Alcindor and Beauger 2011; Seretny, 
Currie et al. 2014).  Acute CIPN symptoms that are readily attributable to neural hyper-
excitability.  This has been verified by axon-excitability testing in peripheral nerves 
(Quasthoff and Hartung 2002; Krishnan, Goldstein et al. 2006; Argyriou, 
Polychronopoulos et al. 2008; Alcindor and Beauger 2011; Seretny, Currie et al. 2014) 
along with numerous demonstrations of disrupted ion channels, e.g. Na, K, and Ca ion 
channels, Ca chelation, and TRP channels, all of which have the potential in increase 
neuronal excitability (Grolleau, Gamelin et al. 2001; Sittl, Lampert et al. 2012; Sittl, 
Lampert et al. 2012; Kagiava, K Kosmidis et al. 2013; Sisignano, Baron et al. 2014; 
Kanat, Ertas et al. 2017). 
However, many fewer studies have examined chronic CIPN, which results in lasting 
impairments to cancer survivors. These impairments are associated with functional 
movement disorders e.g. reduced sensation, impaired balance, discoordination (Saif, 
Syrigos et al. 2010; Marshall, Zipp et al. 2017) and are commonly attributed to dying-
back, length-dependent axon degeneration (Argyriou, Kyritsis et al. 2014; Avan, Postma 
et al. 2015).  However, given that physical evidence from nerve-conduction studies 
suggest that axon degeneration is typically minimal <25% (Burakgazi, Messersmith et al. 
2011), additional mechanisms must be at play.  Chronic CIPN can occur even in cases 
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where no detectable reduction in either nerve-evoked action potentials or epidermal 
nerve density exist (Burakgazi, Messersmith et al. 2011).  Based on reports from our lab 
(Vincent, Wieczerzak et al. 2016), we speculated that rather than by structural 
degeneration alone, chronic CIPN symptoms might depend on functional impairment of 
sensory neurons attributable to neuronal hypo-excitability based on a failure to maintain 
firing in response to fixed levels of stimulation (Vincent, Nardelli et al. 2015; Vincent, 
Wieczerzak et al. 2016).  Discovering no receptor or axonal degeneration provides 
further evidence for this hypothesis, despite this being the pervasive explanation in the 
literature (Vincent, Nardelli et al. 2015; Vincent, Wieczerzak et al. 2016). 
Methodology 
Another limitation is that the effects of platinum-based chemotherapy on neuronal 
excitability have been examined almost exclusively using experimental methodologies, 
which themselves alter neuronal excitability (Button, Kalmar et al. 2008; Yamamoto, 
Tsuboi et al. 2016; Yamamoto, Ono et al. 2016).  With neuronal excitability influenced by 
a myriad of factors (Desai, Rutherford et al. 1999; Rekling, Funk et al. 2000; Kuo, 
Siddique et al. 2005; Grubb and Burrone 2010; Panatier and Robitaille 2012), 
experimental effects confound identification of the actual mechanisms by which 
platinum-based chemotherapy alone alter neuronal excitability (Devor, Govrin-Lippmann 
et al. 1993).  For example, neuronal excitability is altered by damage, which is an 
inevitable consequence with tissue extraction used during in vitro study, a common 
experimental approach utilized  and a likely contributor to abnormal neuronal excitability 
without platinum-based chemotherapy (Tulleuda, Cokic et al. 2011).  Investigations also 
fall short when failing to reproduce the in vivo milieu, including interaction with systemic 
changes induced by platinum-based chemotherapy, e.g. inflammatory and oxidative 
responses known to impact excitability (Pardillo-Díaz, Carrascal et al. 2015; Vezzani and 
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Viviani 2015; Barbosa, Xiao et al. 2017; Tzour, Leibovich et al. 2017; Wang, Zhang et al. 
2017). 
Cancer  
Experimental investigations of CIPN also fall short when failing to reproduce the clinically 
relevant condition when platinum-based chemotherapy effects coexist cancer effects 
(Cain, Wacnik et al. 2001; Klampfer 2011; Zheng, Fang et al. 2012; Cai, Fang et al. 
2015; Pardillo-Díaz, Carrascal et al. 2015; Vezzani and Viviani 2015; West, McCuaig et 
al. 2015; Mager, Wasmer et al. 2016; Barbosa, Xiao et al. 2017; Kovalchuk, Ilnytskyy et 
al. 2017; Tzour, Leibovich et al. 2017; Wang, Zhang et al. 2017). 
To date, cancer is excluded in preclinical studies of CIPN.  However, since the clinical 
utility of chemotherapy rest solely on treating cancer, we must consider how cancer 
contributes to CIPN independent of or in combination with chemotherapy (Ahles 2012; 
Boyette-Davis, Eng et al. 2012; van Erning, Janssen-Heijnen et al. 2016).  Patients with 
tumors located outside the nervous system can exhibit subclinical peripheral neuropathy 
even before chemotherapy or surgical intervention (Ahles 2012; Boyette-Davis, Eng et 
al. 2012; van Erning, Janssen-Heijnen et al. 2016).  These observations are consistent 
with cancer’s effect on signaling pathways known to affect neuronal excitability (Cain, 
Wacnik et al. 2001; Klampfer 2011; Zheng, Fang et al. 2012; Cai, Fang et al. 2015; 
Pardillo-Díaz, Carrascal et al. 2015; Vezzani and Viviani 2015; West, McCuaig et al. 
2015; Mager, Wasmer et al. 2016; Barbosa, Xiao et al. 2017; Kovalchuk, Ilnytskyy et al. 
2017; Tzour, Leibovich et al. 2017; Wang, Zhang et al. 2017).  Several signaling 
pathways intersect with ones affected by chemotherapy, thereby opening the possibility 
for dynamical interaction.  For example, the frequency and gain of neuronal repetitive 
firing is impaired by oxidative stress (Pardillo-Díaz, Carrascal et al. 2015).  Because 
colorectal cancer and chemotherapy treatment each induce oxidative stress (Boyette-
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Davis, Walters et al. 2015), their combination may amplify neuronal dysfunction. The 
prototypical inflammatory cytokines, e.g. IL-1β, TNF-α, IL-6 are activated by 
chemotherapy and colorectal cancer (Klampfer 2011; West, McCuaig et al. 2015; Mager, 
Wasmer et al. 2016).  These pathways present additional sites where dynamical 
interactions may disrupt neuronal excitability (Vezzani and Viviani 2015; Barbosa, Xiao 
et al. 2017; Tzour, Leibovich et al. 2017).  Alternatively, cancer and chemotherapy may 
act through pathways that are hidden from investigations of chemotherapy alone.  These 
data provide strong rationale to suspect that cancer and chemotherapy may dynamically 
interact to exacerbate CIPN. While chemotherapy alone may be necessary to induce 
neuronal dysfunction in preclinical models, it may not be sufficient to capture the 
mechanistic underpinnings of the clinically relevant CIPN condition when cancer is 
present (Sisignano, Baron et al. 2014). 
Overall Objectives  
My overall objective was to investigate the role of cancer in the development of chronic 
neuropathy in living animals. By doing so, I correct many of the limitations of previous 
preclinical studies to gain mechanistic understanding of the clinically relevant chronic 
CIPN to meet the urgent and unmet need of cancer survivors globally. To accomplish 
these objectives, I employed a multi-scale experimental approach centered on in vivo 
electrophysiologic recordings from intact neurons. Further utilization of high-throughput, 
whole transcriptome analysis, protein expression studies, validated measures of 
sensorimotor behavior in awake behaving animals, in silico biophysical modeling, and 
deep-learning decoding algorithms afforded comprehensive insight into establishing the 
independent and combinatorial effects of chemotherapy and cancer on the sensory 
nervous system.  
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CHAPTER 2. GENERAL METHODS 
Animal Care 
All procedures and experiments were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee.  Adult male rats (250-350g) were studied 
in terminal experiments only and were not subject to any other experimental procedures. 
All animals were housed in clean cages and provided food and water ad libitum in a 
temperature- and light-controlled environment in Georgia Institute of Technology’s 
Animal facility. 
Rat model of Colorectal Cancer 
We studied the rat model of colorectal cancer developed in Fisher 344 (F344) rats and 
known as polyposis in rat colon (ApcPirc/+) (Amos-Landgraf, Kwong et al. 2007).  Pirc rats 
were generated from a germline mutation in the Apc gene (Apcam1137/+).  This mutation 
is shared by 80% of patients with colorectal cancer (Kwong and Dove 2009). We studied 
age-matched male rats (4 months).  This age has been previously validated to result in 
100% incidence of animals (Irving, Yoshimi et al. 2014) developing colon cancer and 
was consistent with our population. ApcPirc/+ rats exhibit: regional distribution of tumors 
that best represents that seen in human colorectal cancer (Irving, Yoshimi et al. 2014); 
histopathology and morphology closely resembling human tumors (adenocarcinomas) 
(Washington, Powell et al. 2013; Femia, Luceri et al. 2015), up-regulation of well-
established pro-growth factors, e.g. β-catenin and EGFR and proliferative makers Ki-67 
seen in human carcinogenesis (Amos-Landgraf, Kwong et al. 2007), dramatic increases 
in Wnt signaling believed to be a key factor in human colorectal carcinogenesis (Bienz 
and Clevers 2000), presence of apoptotic resistant cells unique to carcinogenesis 
(Figure 1) (Amos-Landgraf, Kwong et al. 2007; Irving, Yoshimi et al. 2014), oxaliplatin 
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(OX)-induction of apoptosis in colon tumors, survivability (12-15 months) enabling long-
term investigation of OX’s chronic effects (Amos-Landgraf, Kwong et al. 2007). 
Figure 1. 
Immunohistochemical and morphological analyses of healthy and tumor bearing colons. a-f, 
Confocal images of a colon from ApcWT +control rat (a, b) and colon and colon tumors from ApcPirc/++control 
(c, d) and ApcPirc/++ OX rats (e, f). Immunolabeling shows expression of DAPI and Ki-67, and EGFR a 
measure proliferative growth associated with tumor progression. White dotted boxes in wide-field images (a, 
c, e) outline region of interest (b, d, f). White arrows indicate smooth muscle boundary used as anatomical 
reference.  
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Chemotherapy treatment  
OX (Cyclohexane-1,2-diamine; oxalate; platinum(2+)) was injected intraperitoneal (i.p.) 
once a week (10mg/Kg, 1 ml 5% dextrose in DMSO ) in aged matched rats (4 months) to 
achieve a cumulative dose of 70 mg/Kg over 7 weeks, which scales to a human dose of 
420mg/m2 (conversion based on rat body surface area and Km= 6) (Reagan-Shaw, 
Nihal et al. 2008; Nair and Jacob 2016).  Further, this dose minimizes nerve 
degeneration in patients (Grisold, Cavaletti et al. 2012; Park, Goldstein et al. 2013).  
Rats in each group were randomized to receive injections of oxaliplatin (OX), a platinum 
based compound known to induce neuropathy in patients with cancer and shown in our 
previous studies to induce chronic movement disorders (Vincent, Wieczerzak et al. 
2016).  OX was administered by intraperitoneal injection on a human-scaled dose 
schedule (Vincent, Wieczerzak et al. 2016).  The OX treatment schedule resulted in four 
experimental groups used for all studies: ApcWT+control, ApcWT+OX, ApcPirc/++control 










Treatment Schedule and Targets. a, Schematic of treatment schedule of oxaliplain (OX) and vehicle 
control (VC) generating four independent experimental groups in wild-type (ApcWT) and autosomal dominant 
mutation of the adenomatous polyposis coli gene (ApcPirc/+): ApcWT+control, ApcWT+OX, ApcPirc/++control, 
and ApcPirc/++OX rats. b, Diagram of experimental targets of lumbosacral dorsal root ganglia (DRG) and 
muscle for assaying transcriptomes and/or cell-specific protein expression in rat models. 
Clinical dose extrapolation, e.g. converting human OX doses to rat OX doses was based 
on body surface area, which is a better representation of metabolic rate than mass. 
Metabolic rate is a key determinant of drug pharmacokinetic and pharmacodynamics 
and scales non-linearly with animal size, e.g. the body surface area in relation to body 
weight decreases. In other words, larger animals have lower specific metabolic rate (the 
metabolic rate per unit mass) whereas metabolic rate to surface area remains relatively 
conserved (Sharma and McNeill 2009; Nair and Jacob 2016). 
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Throughout treatment, rats were frequently monitored for pain or distress. No individual 
rat reached set criteria established for early removal from the study: greater than 10% 
weight loss, pain or distress assessed by vocalization, absence of grooming, and rats 
show normal exploratory and feeding behaviors.  
Surgical Procedures 
Terminal in vivo experiments were performed 5 weeks after achieving clinically relevant 
chemotherapy doses. They were designed to measure the firing of individual intact 
sensory neurons in response to physiologically relevant muscle contraction and stretch 
with electrophysiological techniques. All in vivo procedures are well established in our 
lab and have been extensively described in previous publications (Haftel, Bichler et al. 
2004; Bullinger, Nardelli et al. 2011; Vincent, Wieczerzak et al. 2016; Nardelli, Powers et 
al. 2017; Vincent, Gabriel et al. 2017). Briefly, rats were deeply anesthetized by 
inhalation of isoflurane (5% in 100% O2), intubated via a tracheal cannula, then 
maintained for the remainder of the experiment (up to 12 hours by 1.5–2.5% in 100% 
O2). Respiratory rate, pCO2, core temperature, pulse rate and pO2 were continuously 
monitored and maintained by adjusting anesthesia and adjusting heat sources. Dorsal 
roots (lumbar L4–6), muscles, and nerves in the left hindlimb were prepared for 
stimulation and recording with the rat fixed in a rigid frame at the snout, vertebral bodies, 
distal tibia, and distal femur (knee angle 120°). Triceps surae muscles (lateral and 
medial gastrocnemii and soleus) were partially freed of surrounding connective tissue 
and marked for their resting length (Lo) at ankle angle 90° before their common Achilles 
tendon was severed at the calcaneus and tied directly to the lever arm of a force- and 
length-sensing servomotor (model 305B-LR; Aurora Scientific). Triceps surae nerves 
were loosely positioned in continuity on a unipolar silver stimulating electrode, and all 
other hindlimb nerves were crushed to reduce extraneous neuronal activity. Dorsal 
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rootlets were freed in continuity from overlying connective tissue and supported on 
bipolar hook electrodes positioned close to the rootlet’s entry into the dorsal spinal cord. 
Exposed tissues were covered with warm mineral oil in pools formed by attaching the 
edges of severed skin to the recording frame (Figure 3). 
Figure 3. 
In Vivo Design. Diagram of anesthetized rat stabilized in spine clamps for physiological recordings. 
Experiments focus on the triceps surae muscles (soleus and medial and lateral gastrocnemius), triceps 
surae nerves, and intra-axonally from single sensory neurons in dorsal roots in the lumbosacral (L4-S2) 
spinal cord.  
 
Bayesian Data Analysis 
General Approach 
To determine the effect of cancer and/or chemotherapy on various parameters, e.g. 
neuronal signaling, sensorimotor behavioral factors, etc., we employed Bayesian data 
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analytic approaches to empirically derive the full joint posterior probability distribution 
of parameters on which inferences were applied. Bayesian analytic techniques were 
chosen because they present noteworthy advantages over frequentist analysis such 
as null hypothesis statistical testing e.g. t-test and ANOVA. Bayesian analytics do not 
require making assumptions that traditional ANOVA necessitates (e.g. normally 
distributed data, heteroscedasticity, multiple-test correction) (Kruschke 2013; 
Kruschke 2014). There is no need to generate sampling distributions, e.g. t, F, 𝑥 2, 
and determine whether the probability that fictitious data generated from the null 
distribution would be more extreme than the observed data i.e. formal definition of p-
values. In addition to their ambiguity, p values provide an incoherent framework for 
reallocation of evidential support because of their high sensitivity to stopping and testing 
intentions (Wagenmakers 2007; Kruschke 2013).  Instead, Bayesian estimation derives 
the entire joint posterior distribution of all parameters simultaneously (Eq. 1) and 
provides the ability to examine individual parameters, such as the threshold of spindle 
firing and peak firing rate in chemotherapy treated animals compared to control without 
the need to correct for multiple tests on the data. In other words, there is no need for p 
values and p value-based confidence intervals (e.g. 95%CI). Instead, Bayesian 
inference and decision making provides a simpler and more intuitive interpretation of 
the evidence by directly examining the posterior distribution to see which parameter 
values and ranges are most credible. Further, unlike null hypothesis statistical testing, 
that can only reject or fail to reject a null hypothesis, by reallocating credibility across 
the parameter space, Bayesian inference generates evidence and uncertainty in that 
evidence to support or refute the null or alternative hypothesis (when a region of 
practical equivalence (ROPE) is defined). While parameter estimation is not unique to 
Bayesian approaches (e.g. maximum likelihood estimation) uncertainty in parameter 
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estimates are typically expressed in the form of confidence intervals which rests on the p 
value along with the limitations discussed above.  
𝑃(𝜃|𝑥) =
𝑃(𝑥|𝜃)	𝑃(𝜃)
𝑃(𝑥) 	 , 𝜃* ∼ 𝑁
(𝜇, 𝜎)	, 	𝑥/,* 	∼ 𝑓1𝜃*2	 
Where θ = (µ, σ) is a set of all unknown model parameters as defined 
above, x denotes a set of mean-centered and standardized dynamic conditioned 
stretch reflex (cSR) response measurements. The conditional distribution of θ given 
data (i.e. P(θ|x)) denotes the posterior distribution. The P(x|θ)	is the distribution of x, 
which is a likelihood function when viewed as a function of model parameters, 
assuming that θ is known. The P(θ) is the distribution of θ without any knowledge on 
data, referred to as a prior distribution. The equation above demonstrates that the 
posterior distribution of θ is proportional to the product of the likelihood of θ given x and 
the prior distribution of	P(θ). 
Inferences 
Bayesian inference, e.g. analogous to traditional hypothesis testing, was performed by 
analyzing the probability mass of the parameter region in question we defined as the 
95% highest posterior density interval (HDI) hereinafter referred to as the HDI. Value 
contained within the HDI are more credible than values outside. The HDI was used to 
make unbiased inferences by directly comparing the posterior probability distributions 
between two (or more) contrasts of interests e.g. mean-comparisons testing. For 
example, when performing a mean comparison test, an HDI of a credible difference 
distribution that does not span zero indicates that the model predictions for the two 
conditions of interest are different from each other. This provides strong unbiased 
evidential support to simultaneously support the alternative and refute the null 
hypothesis that the parameters for both populations are equal. Alternatively, if an HDI of 
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a credible difference distribution spans zero, that indicates the model predictions for the 
two conditions do not differ. Unlike null hypothesis statistical testing, Bayesian 
techniques afford the ability to accept the null hypothesis by defining a ROPE (region of 
practical equivalence) range, e.g. values between -0.1 and 0.1. When the 95% HDI falls 
completely within the ROPE region we declare the ROPE value accepted.  We report the 
expected value for the parameter alongside 95% credible intervals using the HDI unless 
otherwise noted. 
Models  
All models were developed in a fully hierarchal Bayesian framework with the rstanarm 
package (2.18.1) (Gabry and Goodrich 2018) in the R environment (3.5.0) (Team 2018). 
Rstanarm implements regression models in stan (Carpenter, Gelman et al. 2017), which 
are fit using Hamiltonian Markov Chain Monte Carlo sampling to compute credible 
parameter values (Brooks, Gelman et al. 2011; Hoffman and Gelman 2014). For 
intercepts and predictors, we use Student’s t-distribution with mean zero and four 
degrees of freedom as the prior distribution. The scale of the prior distribution is 10 for 
the intercept and 2.5 for the predictors. Each model was run with four independent 
chains for 400 warm-up, 4,000 sampling steps and every second sample (thinning) was 
discarded. For all parameters, the number of effective (n_eff) samples was >500. 
Convergence was assessed and assumed to have reached the stationary distribution by 
ensuring that the Gelman–Rubin shrinkage statistic (rhat, R̂) statistic for all reported 
parameters was <1.05 and Monte Carlo standard error of the parameter means was 
<0.002 (Gelman and Rubin 1992) . We report the expected mean parameter values 
alongside 95% credible intervals using the HDI. For clarity, an example ‘Kruschke style’ 
hierarchical model diagram is included and should be interpreted as the graphical 
representation of mathematical model used for analysis (Figure 4). Reading the 
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diagrams should start at the bottom with a description and nature of the data being 
modeled, then described the likelihood function, then described the prior (top). Diagrams 
were created in LibreOffice (Version: 6.0.6.2). 
Figure 4. 
‘Kruschke style’ hierarchical model graphical diagram. Robust Bayesian linear regression was used to 
model the data yi as a t-distributed random value around the central tendency μi = β0 + β1xi. The intercept β0 
and slope β1 were given broad normal priors that are vague to the scale of data. σ was given an 
uninformative uniform prior, and the normality parameter ν was given a broad exponential prior. 
 
Model Validation 
To estimate and validate model performance of our fitted Bayesian models, for the 
purposes of model comparison and model selection (Geisser and Eddy 1979; Vehtari 
and Lampinen 2002; Ando and Tsay 2010; Vehtari and Ojanen 2012), we estimated the 
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out-of-sample predictive accuracy (Figure 5) using Pareto-smoothed importance 
sampling (PSIS (Vehtari, Gelman et al. 2017)) to perform leave-one-out cross (LOO) 
validation. Exact cross-validation requires refitting models with different training data; 
however, one can approximate LOO by importance sampling (Gelfand, Dey et al. 1992; 
Gelfand 1996). Importance sampling is a simple statistical procedure for 
computing/estimating expectations, e.g. of a particular distribution, while only having 
samples generated from a different, approximating distribution than from the target 
distribution.  Expectations with respect to the target distribution can be estimated by 
weighting the importance samples by the ratio of their densities. However, importance 
sampling can result in noisy estimates (Epifani, MacEachern et al. 2008), when the 
approximating distribution is narrower than the target distribution or when the 
approximating distribution is a poor fit, resulting in the distribution having a heavy right 








Exemplar Graphical Bayesian Model Validation. a, Time series trace plot of the Markov chains (n=4 
overlaid) shows the evolution of parameter (n=5) vectors over the all iterations and indicate chains explored 
the full parameter space. b, Autocorrelation of paramters (columns) illustrate the degree of correlation 
between MCMC samples separated by different lags (x-axis). For example, a lag of 0 represents the degree 
of correlation between each MCMC sample and itself (correlation of 1). A lag of 1 represents the degree of 
correlation between each Markov chain Monte Carlo (MCMC) sample and the next sample along the chains 
(rows). Independent (uncorrelated) samples (autocorrelation of 0) indicate unbiased estimates of 
parameters. No parameters violate autocorrelation. c, Shows overlaid histograms of the (centered) marginal 
energy distribution πE and the first-differenced distribution πΔE. The MCMC No-U-Turn Sampler (NUTS) 
Energy diagnostic identifies overly heavy tails that are also challenging for sampling and quantifies the 
heaviness of the tails of the posterior distribution. The two distributions are well-matched, meaning the 
random walk will explore the marginal energy distribution extremely efficiently. d, Plot shows one line per 
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iteration connecting parameter values at iterations and identifies global patterns to detect divergences if 
present (divergences will be colored in the plot (by default in red). No divergent transitions were detected. e, 
NUTS divergence plot in the top panel shows the distribution of the log-posterior and indicates no 
divergences for all chains. This provides evidential support that chains adequately explore all parts of the 
posterior. The bottom panel shows the distribution of NUTS acceptance statistic approaches 1.  
PSIS is a new approach that provides a more accurate and reliable estimate by fitting a 
Pareto distribution to the upper tail of the distribution of the importance weights. PSIS 
allows the computation of LOO using importance weights that would otherwise be 
unstable (PSIS-LOO). Although alternative validation strategies, e.g. Watanabe-Akaike 
information criterion (Watanabe 2010), are asymptotically equal to LOO, PSIS-LOO 
provides a more accurate and stable estimate of model performance and is more robust 
in the finite cases with diffuse priors (weakly informative), as is true for models in this 
proposal when little is known previously about the cancer and chemotherapy 
interactions.  
PSIS-LOO was quantified by computing standard errors for predictions and for 
comparison of predictive errors between models to definitively test and rank models 
based on predictive accuracy (elpd = expected log pointwise predictive density) (Vehtari, 
Gelman et al. 2017). 
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CHAPTER 3. PROJECT 1 
Introduction 
Chemotherapy can achieve high rates of survival in patients with common cancers 
(André, Boni et al. 2004) but often causes severe side effects, including neuropathy, that 
can limit its use (Cavaletti and Marmiroli 2010; Alcindor and Beauger 2011; Stone and 
DeAngelis 2016).  Debilitating sensory disorders, including pain, paraesthesia, and 
somatosensory loss, reduce quality of life for many patients and can persist for months 
or years after discontinuing chemotherapy (Quasthoff and Hartung 2002; Seretny, Currie 
et al. 2014; Sisignano, Baron et al. 2014).  These neurological disorders occur for up to 
80% of patients receiving commonly used antineoplastic agents, notably antitubulins and 
proteasome inhibitors, as well as platinum-based compounds (Sisignano, Baron et al. 
2014; Avan, Postma et al. 2015), which are the prescribed adjuvant treatment in 50% of 
cancer cases worldwide (Galanski, Jakupec et al. 2005; Johnstone, Park et al. 2014).  
There are few options available for the prevention or treatment of sensory disorders and 
those that exist largely focus on symptomatic management (Hershman, Lacchetti et al. 
2014).  Thus, there is an urgent need to better understand the pathogenesis of sensory 
dysfunction to aid development of mechanism-based therapies. 
Preclinical studies of chronic neuropathy in experimental models of cancer are 
unavailable, possibly because of presumption that chemotherapy alone is sufficient to 
explain the neuropathology.  A recently published meta-analysis identified 341 preclinical 
studies of chemotherapy induced neuropathy, and none assessed interaction between 
chemotherapy and cancer (Currie, Angel-Scott et al. 2018).  Omitting cancer from 
preclinical study produces a fundamental gap in knowledge that may explain why 
treatments for neuropathic side effects of chemotherapy have been unsuccessful in 
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patients with cancer.  Cancerous tumors located outside the nervous system can induce 
cognitive disability and peripheral nervous system dysfunction independent of 
chemotherapy, surgery, or co-morbidities (Ahles 2012; Boyette-Davis, Eng et al. 2012). 
Moreover, cancer provokes dysregulation in immune, metabolic, oxidative and neuronal 
excitability (Reuter, Gupta et al. 2010; Zheng, Fang et al. 2012), all of which are 
identified as targets through which chemotherapy produces neuropathy (Cavaletti and 
Marmiroli 2010).  Convergence of cancer and chemotherapy on the same biological 
processes seems likely to yield non-linear interactions, leading us to hypothesize that 
clinically relevant neuropathy emerges from codependent actions of cancer and 
chemotherapy.   
We tested our hypothesis by uncoupling the independent and combinatorial effects of 
cancer and chemotherapy on sensory neurons in studies of rats that are not feasible in 
human patients.  Here we present original findings to show that sensory neuropathy 
depends on complex systemic interactions between cancer and chemotherapy.  By 
combining cancer and chemotherapy, we reproduce the relevant clinical condition in 
preclinical study of rats to produce the first transcriptional profile of nervous tissue, to 
discover recurrent metabolic reprogramming and perturbed inflammatory and ion 
channel processes distinct from the independent effects of cancer or chemotherapy.  
Parallel codependency is found in novel neuropathic responses of mechanosensory 
neurons, both in their immunohistochemistry for selected voltage-gated potassium ion 
channels and in electrophysiological measures of encoding naturalistic stimuli in vivo.  
Collectively, our data show for the first time that sensory neuropathy emerges from 
codependencies between the systemic effects of cancer and chemotherapy.  Apart from 
identifying new molecular targets for restoring function to mechanosensory neurons, our 
findings provide the fundamental insight that accounting for chemotherapy-cancer 
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combinatorial effects on the somatosensory nervous system is prerequisite for 
developing meaningful treatment or prevention of neuropathy. 
Aim 1: Test the hypothesis that cancer exacerbates 
chemotherapy induced gene dysregulation in the sensory 
nervous system.  
Aim 1 Introduction 
To gain comprehensive and unbiased understanding of treatment effects, we first 
profiled the transcriptomes of lumbosacral (L4-S1) dorsal root ganglia, where sensory 
neurons (Figure 2b) are known to be particularly vulnerable to chemotherapy (Cavaletti 
and Marmiroli 2010).  We studied wild-type (ApcWT) rats and rats carrying an Apc gene 
mutation (ApcPirc/+) (Amos-Landgraf, Kwong et al. 2007) associated with development of 
colon cancer (Kwong and Dove 2009), not only in these rats, but also in 80% of patients 
with colorectal cancer (Kwong and Dove 2009). This allowed us to simulate clinical 
treatment of colorectal cancer in a rat model. We employed the standard-of-care, 
platinum-based chemotherapy agent oxaliplatin (OX), in a human-scaled, dose-
equivalent treatment schedule. This experimental approach provided the best available 
approximation of human colorectal cancer treatment, while enabling controlled 
experimental manipulations and analysis of molecular and functional properties of 
sensory neurons (Irving, Yoshimi et al. 2014). 
Aim Specific Methods 
Tissue Collection 
At the conclusion of in vivo experiments, three to four animals from each of four groups 
were selected for whole-transcriptome analysis alone and did not undergo further 
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analysis.  Dorsal root ganglia (DRG) from the lumbosacral (L5-S2) spinal cord were 
surgically removed (4-6 per animal), washed with sterile saline and immediately flash 
frozen (fresh) in 2-methylbutane (isopentane) pre-chilled in liquid nitrogen.  DRG were 
then stored at -80°C for further analysis (see below).  
RNA Extraction and Amplification  
RNA extraction and amplification were performed according to our previously described 
methods (Lili, Matyunina et al. 2013).  Briefly, RNAs were isolated and purified from 
sensory neurons of DRG (L5-S2) using the mRNeasy Micro KIT (Qiagen, Germantown, 
MD).  Total RNA concentration and integrity was assessed on the Bioanalyzer RNA Pico 
Chip (Agilent Technologies, Santa Clara, CA). Labeling of RNAs was performed with the 
FlashTag Biotin HSR RNA Labeling Kit (Affymetrix, ThermoFisher).  Gene expression 
was determined by microarray analysis on the Affymetrix platform (Rat Transcriptome 
Array 2.0). 
Microarray data analysis 
In total, 13 (four groups with biologic triplicates per group (4 biologic replicates from 
ApcPirc/++OX group) global transcriptional expression data sets were generated in this 
study.  Raw mRNA expression data were processed using Affymetrix Expression 
Console (EC) software Version 1.4.  Raw data probes were normalized using SST-RMA 
algorithm. Differentially expressed genes (DEG) were determined through a linear fixed 
effects model (limma (Smyth 2004; Smyth 2005)) with a robust empirical Bayes 
(eBayes) framework(Phipson, Lee et al. 2016) to moderate the residual variances 
(Smyth 2004; Smyth 2005).  This has the effect of increasing the effective degrees of 
freedom by which gene-wise variances are estimated, thus reduces the number of false 
 24 
positives for genes with small variances and improves power to detect DEG with larger 
variances (Ritchie, Silver et al. 2007).  
Unsupervised multivariate analysis 
DEGs were subjected to paired multivariate analyses to discover latent data structure. 
We serially linking two analytic techniques, Principal Components Analysis (PCA) and 
Hierarchical clustering. This stabilized clustering performance and reduced 
dimensionality to a more tractable number of continuous variables containing the most 
important information on which clustering algorithms are focused which leads to a better 
clustering solution (Husson, Josse et al. 2010; Argüelles, Benavides et al. 2014).  PCA 
and visualization was applied to DEGs with the factoextra (Kassambara and Mundt 
2016) and FactoMineR (Husson, Josse et al. 2010) packages.  PCs capturing high-level 
structure were then employed to drive hierarchical clustering.  Hierarchical clustering 
and heatmaps were visualization with the gplots package (heatmap.2) (Warnes, Bolker 
et al. 2016) in the R environment (3.5.0) (Team 2018). Hierarchical-clustering, using the 
ward.D2 method (Murtagh and Legendre 2014) were applied to the eBayes-filtered gene 
set to obtain unsupervised visualization of the gene clusters coordinately expressed 
among the different experimental groups. Prior to hierarchical clustering, genes were 
standardized across the samples to a mean of zero and an s.d. of 1. Subclusters were 
derived using the R function cutree (Becker, Chambers et al. 1988). 
Pathway and Gene Set Enrichment Analysis  
To extract biological meaning from large lists of differentially expressed genes acquired 
through high-throughput technologies, e.g. transcriptomics, one must utilize bioinformatic 
support. Pathway enrichment analysis is one such analytic approach through which 
high-throughput, typically -omics, data are analyzed to uncover a variety of biological 
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mechanisms associated with a physiological process, e.g. diseases, development, etc. 
Detailed descriptions and protocols have been described previously (Huang, Sherman et 
al. 2008; Huang, Sherman et al. 2008); therefore, only a brief description follows. 
Pathway enrichment analysis was conducted on subclusters of named genes using 
DAVID (Database for Annotation, Visualization, and Integrated Discovery) and g:Profiler 
to pinpoint significantly enriched pathways or biological processes (Huang, Sherman et 
al. 2008; Huang, Sherman et al. 2008).  Biological processes and pathways are 
composed of group of genes as opposed to individual genes and are derived from the 
collective knowledgebase of published literature e.g. annotation database Gene 
Ontology (GO).  Biological processes link individual genes to a broader biological 
concept or pathway and typically contain many tens to hundreds of genes. It should be 
noted that different biological processes can have some degree of redundancy of their 
composition. 
The foundations of pathway enrichment analysis rest on the idea that if a biological 
process or pathway is truly abnormal in a disease, the co-functioning genes should have 
a higher potential to be selected for as a relevant group by the high-throughput 
screening technologies as opposed to studying individual genes. This shift from focus on 
individual genes to large gene lists increases the likelihood of identifying correct 
biological processes most pertinent to the disease or biological phenomena under study 
and reduces the likelihood of false positive findings.  We further increase statistical 
power by submitting subclusters, co-regulated (up or down) probe sets, for testing that 
were previously separated during our initial multivariate approach (Hong, Zhang et al. 
2014). All biological processes with adjusted P < 0.05 were considered significantly 
enriched. g:Profiler 3-500 (min-max) Benjamini Hochberg FDR correction intersection 
terms (2) only annotated genes were searched.   
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Parallel identification of pathways enrichment was performed by GSEA (gene-set 
enrichment analysis). GSEA underlying statistical construct is independent of DAVID. 
GSEA can uncover novel sets of functionally related genes by focusing on all detected 
(above-background) genes. GSEA is unbiased in this regard in that is reduces arbitrary 
cut-off factors in the typical gene selection step utilized in traditional analyses; and it 
uses all information by allowing genes with even minimal change that would otherwise 
not pass the selection threshold. These advantages afford the detection of even subtle 
enrichment signals. GSEA accomplishes this by leveraging list rank information without 
using a threshold typically applied in overlap statistics like hypergeometric testing to 
define genes as members at the top or bottom of a ranked list of genes. 
The Molecular Signature Database v 6.2 (C2-CP: canonical pathways; C3- MIR: 
microRNA targets; C3- TFT: transcription factor targets; C5-BP: GO biological process; 
C5- CC: GO cellular component; C5- MF: GO molecular function C7: immunologic 
signatures gene sets) with the permutation type set to ‘gene set,’ 15-500 (min-max), to 
calculate statistical significance, as suggested for fewer than seven replicates; default 
settings were applied to all the other options. For GSEA, a false discovery rate (FDR) of 
<0.2 was considered statistically significant. Selecting appropriate reference background 
for pathway analyses is a potential pitfall since the different gene reference background 
settings may greatly impact the enrichment scores. Even though there is no ‘gold’ 
standard for the reference background, we followed the widely utilized procedure of 
setting the reference background to the pool of genes that could be potentially be 
selected, e.g. total genes evaluated in an -omics study. Specifically, all pathway 
analyses performed utilized the same Affymetrix platform Rat Transcriptome Array 2.0 
as the background list of genes.  
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Targeted Transcriptional Analysis  
Complementary supervised analysis of DEGs leveraged knowledge of proteins known to 
be expressed at sensory neuron receptor endings that directly (Simon, Shenton et al. 
2010; Woo, Lukacs et al. 2015; Carrasco, Vincent et al. 2017) or indirectly (Bewick and 
Banks 2015; de Nooij, Simon et al. 2015) regulate excitability. In addition, due to 
incomplete knowledge of the full suite of proteins that are necessary and sufficient for 
normal function (Bewick and Banks 2015), we expand targeted transcriptional analysis 
to incorporate gene families, including: ion channels, GPCRs, and channel regulators.  
Results  
Transcriptional profiling of sensory neurons 
We employed an empirical Bayesian (eBayes) linear model (Smyth 2004) to modify 
residual variances on a total of 31,042 (22,875 named) genes and identified 3,426 
differentially expressed genes (DEG) across all groupwise contrasts (PeBayesAdj < 0.005). 
Subsequent post hoc analysis identified DEG from all possible contrasts (fold-change 
(FC) ≥1.2 and ≤-1.2). Overlap between DEGs retrieved from individual comparisons is 
illustrated in (Figure 6a). In keeping with the notion that chemotherapy and cancer act 
through similar molecular mechanisms, we found overlap of 112 DEG affected 
independently by cancer and chemotherapy (Figure 6a). Of note, we found that 73.8% 
(n=1,704) of all DEG (n=2,307) were uniquely affected when cancer and chemotherapy 
interacted (ApcPirc/++OX) Figure 6a). This finding demonstrates the first evidence that 
cancer exacerbates genetic dysregulation induced by chemotherapy, unmasking a more 
than four-fold increase in DEG. 
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Figure 6. 
Cancer-chemotherapy codependence amplifies transcriptional dysregulation. c, Venn-diagram 
distribution of significantly differentially expressed genes from the lumbosacral DRG among all groupwise 
contrasts. Significance determined by both P<0.005 and fold-change (FC) ≥1.2 and ≤-1.2 using a Bayesian 
moderated linear fixed effects model (eBayesAdj). d, Group correlation determined by principal-component 
(PC) analysis of significantly differentially expressed genes. Genes were visualized in the new 3D composite 
space created by PC1-3. Effects of independent chemotherapy (ApcWT+OX) or cancer (ApcPirc/++control) and 
their combinatorial (ApcPirc/++OX) treatment are indicated by curved arrows; dots represent individual 
animals. e, Bar graphs of the mean values of PC1, PC2, and PC2. Error bars represent s.e.m. * indicates 
statistically significant differences between experimental groups as empirically derived from hierarchical 
Bayesian model (stan_glm). 
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Next, we performed two independent downstream analyses (Figure 7) to test for 
interaction and determine which biologic processes might be involved in pathogenesis of 
sensory disorders.  First, we subjected the eBayes filtered database to unsupervised 
principal component (PC) analysis. DEG were visualized in the new 3D composite space 
created by PC1-3 (Figure 6b) that explained 83.98% of the variance and clearly 
segregated the four experimental groups. Inspection of individual PCs revealed 
significant evidence of non-linear interactions between cancer and chemotherapy 
captured in PC1 (65.6% of explained variance), whereas PC2 (11.14%) and PC3 
(7.24%) separated the effects of cancer and chemotherapy, respectively (Figure 6c). 
Second, we drove unsupervised hierarchical clustering onto the PC1 solution to identify 
groups of coregulated genes that express interaction (Argüelles, Benavides et al. 2014) 
(Figure 8a).  Analysis identified two clusters of genes displaying distinct, but internally 
consistent expression profiles clearly representing patterns of interaction (Figure 8a, C1 











Steps outlining parallel independent transcriptome analyses. Data analysis flowchart depicts the multi-
step (split into a, b, and c streams) approach utilized for transcriptome analysis, inferences and downstream 
protein level validation. A detailed description of each step is available in the Online Methods Sections. 
Each box highlights specific analytic techniques, statistical packages (when relevant), and corresponding 
figures as reference. Principal component analysis, PCA; gene set enrichment analysis, GSEA; principal 
components, PC; Database for Annotation, Visualization and Integrated Discovery, DAVID; 
immunohistochemistry, IHC.  
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Figure 8. 
 Cancer-chemotherapy interaction disrupts distinct biological processes. a, Heatmap of the top 
differentially expressed genes in the sensory neurons identified by PC1 driven hierarchical-clustering 
(biological triplicates n= 3 for ApcWT+control, , ApcWT+OX, ApcPirc/++control and four biologic replicates for 
ApcPirc/++OX). Data were mean-centered and s.d. normalized before clustering; upregulated and 
downregulated genes (row) are shown in red and blue, respectively. White and grey bars (C1 and C2 
respectively) display the main clusters from gene level hierarchical-clustering and were chosen for clarity, 
while subclusters (a-c) highlight unique biologic characteristics within the main clusters.  b, Clusters showing 
distinct up- or downregulation of key biological processes (Gene Ontology (GO) terms) and pathways (Kyoto 
Encyclopedia of Genes and Genomes (KEGG)). Selected pathway and gene ontology terms significantly 
associated (false discovery rate [FDR] ≤ 0.25) with misregulated transcripts in individual clusters are listed 
on the left of each gene cluster with significance indicated by horizontal bars (-log10(FDR)). The vertical bar 
graphs on the right compare mean±s.d. of gene expression levels in each subcluster (Table S1).  c, 
Confocal image of a dorsal root ganglia immunostained against interleukin 6 (IL6). Scale bar, 40 μm. Gene 
expression (d) and receptor protein expression (e, mean fluorescence intensity (MFI)) of IL6 as determined 
by transcriptional profiling and cell-specific immunohistochemistry of large diameter sensory neurons 
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(>30μm). Numbers (n) identify sample size for each group.  * indicates statistically significant differences 
between experimental groups as empirically derived from hierarchical Bayesian model (stan_glm). ** 
indicates eBayesAdj<0.005 and fold-change (FC) >1.5 using a Bayesian moderated linear fixed effects 
model. Data presented as mean±s.d. 
 
We then subjected clusters of named genes (Table S1) to pathway-enrichment analysis 
(Reimand, Kull et al. 2007; Huang, Sherman et al. 2008) and identified unique 
subclusters (Figure 8a) expressing dysregulation in distinct biological processes (Figure 
8b, see Methods: Pathway and Gene Set Enrichment Analysis). In keeping with the 
notion that combinatorial effects of cancer and chemotherapy (OX) reflect convergence 
onto shared signaling pathways, genes mediating inflammatory response, e.g. 
interleukin 6 (Il6) (PeBayesAdj=7.82× 10−6), Ptgs2 (PeBayesAdj=0.0028) and Cxcr4 
(PeBayesAdj=3.74× 10−7), and reactive oxygen species processes, e.g. Hmbox1 
(PeBayesAdj=0.001), were found to be among the most upregulated in cluster 1a (C1a) 
(Figure 8b). Notably, we observed substantial induction of genes encoding glycolytic and 
carbohydrate metabolic processes (FDR ≤ 1.83x10-3, C1a; Figure 8b) in the ApcPirc/++OX 
neurons. Coincident with these changes was a statistically significant down-regulation of 
genes mediating lipid metabolism (C2a), suggestive of pervasive metabolic dysfunction 
beyond the small subset of dysregulated mitochondrial related processes that we found 
in response to ApcWT+OX or ApcPirc/++control alone (Figure 8b; Figure 9a,b) and similar 
to dysfunctional effects previously suggested (Cavaletti and Marmiroli 2010). Among 
additional unique transcripts downregulated in ApcPirc/++OX neurons, Figure 8b highlights 
multiple deficits in processes related to extracellular matrix control, mechanical stimulus 
transduction (C2a), DNA-binding, RNA polymerization (C2b), transcription factor activity, 
hormone signal transduction (C2c and Table. S1). Furthermore, we observed genes in 
C1b and 2a that represent specific dysregulation of neuronal and sensorimotor function, 
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e.g. ion-channel genes determining neuronal excitability along with coincident down-
regulation of locomotion.  These data provide the first evidence that codependent 
neuropathy induces broad metabolic reprogramming, e.g. increased glycolytic and 
decreased lipid metabolism, consistent with cancers capacity to corrupt metabolic 
processes (DeBerardinis, Lum et al. 2008; Hay 2016), which extends knowledge beyond 










Pathway analysis and GSEA based comparison of the independent effects of cancer and 
chemotherapy show convergence of mitochondrial dysfunction. List of enriched gene sets in sensory 
neurons identified by GSEA (queried against MSigDB, C2-CP: canonical pathways; C3- MIR: microRNA 
targets; C3- TFT: transcription factor targets; C5-BP: GO biological process; C5- CC: GO cellular 
component; C5- MF: GO molecular function C7: immunologic signatures gene sets from the comparison of 
a, ApcWT+control and ApcWT+OX and b, ApcWT+control and ApcPirc/++control groups. Individual frames 
identify functional relatedgroups of gene sets expressing distinct up- or downregulation as compared with 
control. Representative enrichment plots are shown on the right. Heat-map representation of leading-edge 
genes are shown on the right of each enrichment plot highlight key mitochondrion-related proc, such as 
translation and biogenesis in both ApcWT+OX and ApcPirc/++control neurons, and key neuron myelinatio-
related processes. Statistical signifi- cance was determined by permutation testing with normalized 
enrichment score (NES) and Benjamini–Hochberg false discovery rate (FDR) < 0.25.  
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Markers for nerve degeneration, inconsistently observed in patients treated with 
antineoplastic drugs (Burakgazi, Messersmith et al. 2011) exhibited mixed results.  While 
we observed few significantly downregulated genes associated with myelination 
processes (C2b; P ≤ 7.12x10-3, Figure 8b), we also found significant induction of 
processes involved in the preservation of neurons (e.g. enrichment of negative 
regulation of apoptosis P ≤ 5.96 x 10-3) in C1a that is related to the synergistic effects of 
cancer and chemotherapy, i.e. where cancer and chemotherapy impart influence in the 
same direction. Mixed results from these data suggests heterogeneous neuronal 
populations in the DRG may contain discrete subpopulations with selective vulnerability 
whereas others are resistant to degeneration, which is consistent with mixed results 
seen in human studies (Burakgazi, Messersmith et al. 2011) and highlights the need for 
future cell-type specific investigations that are currently unavailable.  
Global dysregulation of neuron transcriptomes 
We then used gene-set enrichment analysis (GSEA) as a second independent tool to 
investigate the cellular processes underlying codependent neuropathy. We initially 
focused on the comparison of ApcWT+OX and ApcPirc/++OX (Figure 10a: how cancer 
alters the independent effects of chemotherapy) and ApcPirc/++control and ApcPirc/++OX 
(Figure 10b: how chemotherapy alters the independent effects of cancer) and 
interrogated entire data sets against the Molecular Signatures Database (Table S2). Two 
novel conclusions can be drawn from the GSEA findings. First, GSEA independently 
validated codependencies of cancer and chemotherapy in the DEG identified by 
transcriptional profiling using paired unsupervised analysis (Figure 10a, b). GSEA 
corroborated downregulation of lipid metabolic pathways (normalized enrichment score 
(NES)=1.73) and upregulation of glycolytic pathways (NES=−1.94) in ApcPirc/++OX 
sensory neurons when compared with either chemotherapy (Figure 10a) or cancer alone 
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(Figure 10b). Focusing analysis on pathways directly involved in neuronal signaling 
confirmed dysfunction in peripheral neuron ensheathment in the absence of evidence 
supporting neuron specific apoptotic response (FDR>0.83) (Figure 10a). Second, GSEA 
exposed dysregulation of genes relevant to neuronal excitability particularly potassium 
ion channels and transporters, and others participating in synaptic communication, e.g. 
SNARE and glutamatergic transmission (Figure 10a, b). Dysregulation of these and 
other gene sets (e.g. proinflammatory chemokines) was not predicted from the 
independent effects of cancer or chemotherapy alone. (Table S2). Unlike previous 
studies that consistently report dysregulated voltage-gated sodium channels (Sittl, 
Lampert et al. 2012), we find little evidence of differentially expressed sodium channels 
or disrupted regulatory pathways (Sittl, Lampert et al. 2012).  Instead, we find targeted 
DEG related to potassium ion channels unlike those previously identified.  We draw two 
conclusions from these data.  First, ion channel clusters are differentially vulnerable to 
codependent neuropathy.  Second, chronic neuropathy may be mechanistically linked to 





GSEA and pathway analyses test codependence of cancer and chemotherapy. Enriched gene sets in 
sensory neurons identified by gene set enrichment analysis (GSEA: MSigDB, C2-CP: canonical pathways; 
C3- MIR: microRNA targets; C3- TFT: transcription factor targets; C5-BP: GO biological process; C5- CC: 
GO cellular component; C5- MF: GO molecular function C7: immunologic signatures gene sets from the 
comparison of a, ApcWT+OX and ApcPirc/++OX and b, ApcPirc/++control and ApcPirc/++OX groups. Individual 
frames (horizontal grey bars) identify functional related (internally consistent) groups of gene sets 
expressing distinct up- or downregulation as compared with ApcWT+OX. Number of overlapping genes 
displayed in parentheses to the right of the corresponding GO term. Representative enrichment plots are 
shown in the middle column. Heat-map representation of leading-edge genes is shown on right. c, Heat-map 
representation of enriched individual gene sets, identified by GSEA, in sensory neurons for chemotherapy 
(bottom rown), cancer (middle row), and the combination of cancer (ApcPirc/+) and chemotherapy (OX) (top 
row). Gene sets are grouped into functionally related cohorts. Gene sets not reaching statistical significance 
indicated by (X). d, Chord diagram shows enriched pathways (Database for Annotation, Visualization, and 
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Integrated Discovery; DAVID) on the right, and genes contributing to enrichment are shown on the left. 
Squares on left indicate genes differentially expressed in  ApcWT+OX, ApcPirc/++control, or ApcPirc/++OX 
groups compared to control (see the key for gene differential expression). Statistical significance determined 
by permutation testing with normalized enrichment score (NES) and Benjamini–Hochberg false discovery 
rate (FDR) < 0.25. DEG, differentially expressed genes; ROS, reactive oxygen species: ECM, extracellular 
matrix. 
Summary 
Taken together, our analyses indicate significant dysregulation of genes and proteins 
mediating core cellular processes of ApcPirc/++OX sensory neurons. Our integrated 
transcriptomics and protein level findings confirmed that cancer and chemotherapy effect 
common processes (Ahles and Saykin 2007; Reuter, Gupta et al. 2010; Argyriou, Bruna 
et al. 2017).  Moreover, our findings support our central hypothesis that clinically relevant 
neuropathy depends on systemic interaction between cancer and chemotherapy by 
showing for the first time that cancer-chemotherapy codependence exacerbates 
neuropathy and revealing it operates through distinct mechanistic pathways, unpredicted 
from cancer or chemotherapy alone.  
 
Aim 2: Test the hypothesis that cancer-chemotherapy 
codependent genetic dysregulation is conserved at a protein 
level. 
Introduction 
Because inflammatory pathways play multiple roles in regulating neuron function 
(Vezzani and Viviani 2015), we focused attention on their significant response to 
codependent neuropathy.  We selected the most dysregulated gene in the inflammatory 
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pathways, Il6, for the first molecular validation by assessing gene—protein 
correspondence.  
Aim Specific Methods 
Tissue Collection 
At the conclusion of in vivo experiments, rats were overdosed with isoflurane inhalation 
(5%) then immediately transcardially perfused with cold vascular rinse (0.01 M PBS pH 
7.4) followed by room temperature fixative (2% paraformaldehyde in 0.1 M PBS, pH 7.4). 
Muscles and dorsal root ganglia were quickly dissected and post-fixed for one hour in 
the same fixative. After a brief wash in a 0.1 M PBS, tissues were incubated in 0.1 M 
PBS containing 20% sucrose at 4°C overnight. After DRG removal, colonic tumors from 
ApcPirc/+ rats were dissected and counted prior to post fixation for immunohistochemical 
analysis.  
Immunohistochemistry 
Details of our immunohistochemistry procedures have been previously described 
(Carrasco, Vincent et al. 2017).  Briefly, 50-µm thick sections of skeletal muscles, DRGs, 
and tumors were cut using a Cryostat (Leica). Tissues sections from all treatment 
groups were processed simultaneously. All tissue sections were incubated overnight in 
primary antibodies diluted in blocking buffer (5% normal goat serum, 0.3% Triton100 in 
PBS). The primary antibodies used were as follow:  rabbit polyclonal anti-NaV1.6 (ASC-
009, Alomone Laboratories, 1:200), rabbit polyclonal anti-NaV1.1 (ASC-
001, Alomone Laboratories, 1:300), rabbit polyclonal anti-NaV1.7 (ASC 
008, Alomone Laboratories,1:100), rabbit polyclonal anti-Kv3.3 (APC-
102, Alomone Laboratories, 1:300), mouse monoclonal anti-Kv1.1 (K36/, NeuroMab, 
University of California Davis, 1:300), guinea pig  polyclonal anti-VGLUT1 (135-
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104 Synaptic Systems, 1:300), chicken polyclonal anti-neurofilament protein (NF-
H, Aves Laboratories, 1:200), mouse monoclonal anti-ASIC2, (E-20, Santa Cruz 
Biotechnologies,1:200), mouse monoclonal anti-EGRF (SC-120, Santa 
Cruz Biotechnolgy, 1:100), mouse monoclonal anti-KI67 (SC-23900, Santa Cruz 
Biotechnology, 1:100), mouse monoclonal anti-IL6 (SC-57315, Santa Cruz 
Biotechnology, 1:100).  After washing with PBS, tissue sections were incubated with 
appropriate fluorescent-conjugated secondary 
antibodies (Jackson ImmunoResearch Laboratories) diluted in blocking buffer, for 1 hr. 
at room temperature. Following washes with PBS, slides were 
mounted using Vectashield containing DAPI (Vector Laboratories) in order to label cell 
nuclei.  
3D Digital Reconstructions and Anatomical Quantifications 
Z-axis stacks of images of muscle spindles receptor endings, DRGs and tumors were 
constructed by sequentially imaging using a confocal microscope (LSM 700A, Zeiss). 
Muscle spindles terminals z-stacks (1μm steps) were captured with a 40X oil immersion 
objective (N.A 0.6) at 0.6 digital zoom. DRG and tumors z-stacks (1μm steps) were 
captured with a 20X objective (N.A 0.4) at 0.6 digital zoom. Stacks of images were 
processed and analyzed using Amaris (Bitplane) or imageJ (NIH) imaging software. 
Figures present images as flat maximal projections of the sum of the z-axis optical 
slices. Analysis of neuron receptor endings (spindles) and soma (DRG) were performed 
by an investigator blinded to treatment group. Immunoreactivity in nerve terminals and 
DRG was determined by measuring the mean pixel intensity of on each en-face portions 
of the terminal (visualized by the VGLUT1 staining) observed on every 1 um single 
image or on the medium and large size cell somas observed on the flat maximal 
projections of the z-stacks images respectively.   
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Results  
Dysregulation is conserved at protein level 
Sensory neurons in dorsal root ganglia were immunolabeled with monoclonal antibodies 
targeting IL6 (Figure 8c). As predicted from the transcriptional profiling (Figure 8d), the 
IL6 protein was constitutively expressed in ApcWT+control rats at lower levels than in 
ApcPirc/+ control animals or ApcWT+OX animals, and at significantly higher levels in 
ApcPirc/++OX neurons (Figure 8e), demonstrating that codependent neuropathy was 
conserved in protein expression (Figure 8e and Figure 11). Previous studies implicate 
IL6’s capacity to mediate hyperexcitability and morphological changes associated with 
neuron death (Nelson, Ur et al. 2002). However, these studies restricted investigation to 
acute neurotoxicity, which limits generalizability to symptoms that persist long after 
treatment. Our data present the first evidence that Il6 (IL6) expression levels remain 
elevated long after treatment cessation without observable morphological changes. We 
show that codependent neuropathy significantly increases Il6 (IL6) when compared to 
chemotherapy or cancer alone. In light of IL6’s capacity to decrease excitability following 
chronic exposure (Nelson, Ur et al. 2002), our data suggest that neuronal dysfunction 
(see below) as a result of codependent neuropathy may be expressed as hypo-








Immunostaining of sensory neurons in dorsal root ganglia. Whole-mount staining and confocal axial 
projections of DRG neurons highlight expression of IL6 (a) in ApcWT+control, ApcWT+OX, ApcPirc/++control, 
and ApcPirc/++OX rats 
 
Novel voltage-gated ion channel dysfunction  
Sensory deficits, e.g. somatosensory and hearing loss, are commonly reported by 
patients long after cessation of chemotherapy, but knowledge of the combined effects of 
cancer and chemotherapy is missing. Mechanosensory systems, e.g. cochlear hair cells, 
and various somatosensory neurons in skin and muscle are responsible for encoding 
this information and exhibit deficits following chemotherapy (Avan, Postma et al. 2015). 
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We therefore next focused on identifying the combined effects of cancer and 
chemotherapy on a representative member of mechanosensory neurons, called muscle 
spindles. Muscle spindles share many of the molecular mechanisms (Bewick and Banks 
2015) underlying mechanotransduction and encoding found in this broad class of 
sensory neurons (e.g. hair cells (Chalfie 2009), Merkel (Maksimovic, Nakatani et al. 
2014)). Further, signaling by these neurons encodes sensory features of muscle 
mechanics necessary for perceiving (proprioception) and coordinating body position and 
movement, functions which, when impaired, have the potential to explain persistent 
disorders in patients (Proske and Gandevia 2009).  We performed targeted analyses of 
our transcriptome database by querying differentially expressed genes identified in 
ApcPirc/++OX rats compared to all other groups against genes encoding proteins known 
to be constitutively expressed in mechanosensory neurons that mediate unique 
contributions to neuronal signaling (Figure 12) (Bewick and Banks 2015; Woo, Lukacs et 
al. 2015; Carrasco, Vincent et al. 2017).  We found no evidence for independent nor 
combinatorial effects of cancer or chemotherapy at the genetic level (Figure 16a and 
Extended Data) for channels mediating mechanotransduction (e.g. Asic2, Piezo2, 
ENaCs), signal amplification, and spike encoding (e.g. Scn1a (Nav1.1), Scn8a (Nav1.6), 
Scn9a (Nav1.7), Cacna1s,-c,-d, -f (Cav1.1-4),  Kcnn2 (SK2), Kcna1 (Kv1.1) which was 
subsequently confirmed in downstream immunohistochemical analyses (Figure 13, 
Figure 14, Figure 15). 
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Figure 12. 
Model of molecular determinants of neuronal signalling of sensory neurons. Model of mechanically-, 
voltage- and ligand-gated ion channels and their distribution in muscle spindle Ia primary ending. The 
intrafusal muscle fiber (red) is wrapped by an annulospiral ending (green) and a preterminal axon that 
extends unmyelinated from the terminal to the heminode (pink) followed by a myelinated axon. Dotted-boxes 
represent specific regional distributions believed to underlie specific functional characteristics of neuronal 
signaling e.g. mechanotransduction, receptor potential amplification, spike encoding, and autogenic 
feedback. Red circles with slashes indicate no gene and protein level evidential support for involvement in 
mediating cancer-chemotherapy codepedent neuronal dysfunction. Bold question marks (?) indicate protein 
as a possible candidate due to evidential support from transcriptome, yet protein level confirmation is 
unavailable. a, Deformation of the receptor ending opens mechanotransduction channels that initiate 
excitatory currents mediated by ASIC2/3 (Simon et al 2010), Piezo2 (Woo et al 2015), ENaCa,b,d,g and to 
some extend TRP channels (Bewick and Banks 2015). Various Nav (Carrasco et al 2017) and Cav (Bewick 
and Banks 2015) channels are believed to amplify receptor potentials (b) and assist transmission toward 
encoding in the preterminal axons (c). d, Recent discovery of specific distribution of Nav channels in the 
heminodes (Carrasco et al 2017) are believed to underlie encoding of action potential similar to axon initial 
segments in other systems (Foust et al 2010). e, three components known to regulate auto- genic 
glutamatergic synapses in proprioceptors critical for signalling.  
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Next, we performed cell-specific immunohistochemical analyses to test gene–protein 
correspondence. We found no evidence to suggest dysregulated protein expression nor 
did evidence emerge to suggest altered protein distributions for most proteins, including 
those mediating mechanotransduction (ASIC2) (Figure 13), signal amplification (Nav1.1, 
Nav1.6 shown in Figure 14, and Nav1.7), spike encoding (Kv1.1), and mechanosensory 
sensitivity (VGLUT1) (Figure 15). These findings demonstrate that many of the 
molecular mechanisms responsible for mechanotransduction and determining excitability 
of mechanosensory neurons were preserved in the ApcPirc/++OX rats. These findings 
narrow the field of candidate mechanisms for which treatment might reasonably restore 
normal function.  
Figure 13. 
 ASIC2 immunostaining of proprioceptive sensory neurons receptor endings. Whole-mount staining 
and confocal axial projection of the preterminal axons and annulospiral receptor endings of proprioceptive 
sensory neurons showing single channel images of ASIC2 (red) from: a, ApcWT +control rat; b, 
ApcPirc/++control; c, ApcWT+OX; d, and ApcPirc/++OX rats. 
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Figure 14. 
 Nav1.6 immunostaining of proprioceptive sensory neurons receptor endings. Whole-mount staining 
and confocal axial projection of the preterminal axons and annulospiral receptor endings of proprioceptive 
sensory neurons showing single channel images of Nav1.6 (red) and NF-H (green) in top row from: a, ApcWT 
+control rat; b; c, ApcWT+OX; d, and ApcPirc/++OX rats. Bottom rows show Nav1.6 distribution in heminodes 





vGlut1 immunostaining of proprioceptive sensory neurons receptor endings. Whole-mount staining 
and confocal axial projection of the preterminal axons and annulospiral receptor endings of proprioceptive 
sensory neurons showing single channel images of vGlut1 (green) from: a, ApcWT +control rat; b, 
ApcPirc/++control; c, ApcWT+OX; d, and ApcPirc/++OX rats. 
 
Having exhausted examination of proteins known to be expressed in mechanosensory 
neurons, we extended our search to include ion channels yet to be identified, but known 
to regulate neuronal signaling in other classes of neurons (Rudy, Chow et al. 1999; 
Akemann and Knöpfel 2006; Espinosa, Torres-Vega et al. 2008; Waxman and Zamponi 
2014).  As one of the most dysregulated voltage-gated ion channels, Kcnc3 (encoding 
protein Kv3.3) emerged as a novel candidate (Figure 16a, b, Figure 17). Pharmacologic 
and genetic perturbation of Kv3.3 (Kcnc3) impairs neuronal signaling  (Akemann and 
Knöpfel 2006; Espinosa, Torres-Vega et al. 2008) and is causally linked to ataxias 
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(Figueroa, Minassian et al. 2010) that are consistent with functional deficits observed in 
patients with cancer long after cessation of chemotherapy. We then immunolabeled 
sensory cell bodies in dorsal root ganglia and their receptor endings taken from 
ApcWT+control with monoclonal antibodies targeting Kv3.3, which revealed the first 
evidence of this ion channel in all large diameter cell bodies in the dorsal root ganglia 
that supply mechanosensors (Figure 16c and Figure 18) and endings (Figure 16e). 
Results of comparison across experimental groups indicate that Kv3.3 expression was 
significantly lower in ApcPirc/++OX compared with ApcWT+control (Figure 16d,), 
ApcPirc/++control, or ApcWT+OX (Figure 18), demonstrating that codependent dysfunction 
is conserved in cell-type specific protein expression. Notably, while we discovered 
correspondence between protein and gene dysregulation, genetic dysregulation 
appeared larger. This finding may represent the expression of a faulty epigenetic 
regulatory process that is incompletely compensated at the protein level.   Moreover, 
conserved Kv3.3 expression in neuromuscular junctions suggests that Kv3.3 dysfunction 









Targeted transcriptional analysis reveals mechanisms for cancer-chemotherapy interaction. a, 
Volcano plot comparing up- and downregulated genes in ApcPirc/++OX and ApcWT+control sensory neuron 
transcriptomes. Annotation of genes involved in mechanotransduction, signal amplification, action potential 
generation and maintenance is shown. Significance was determined as Benjamini–Hochberg FDR < 0.01 
and log2fold change ≥ 1.  b,  Gene expression of Kcnc3 encoding Kv3.3, as determined through 
transcriptional profiling (Kcnc3: 1369133_a_at). c, Confocal images of dorsal root ganglia immunolabeled 
against Kv3.3 illustrates expression of ApcPirc/++OX relative to ApcWT+control neurons. d, Quantification of 
receptor protein expression (mean fluorescence intensity (MFI)) of Kv3.3 determined through averaging over 
all annulospiral endings (617 from 12 ApcWT+control neurons, 434 from 10 ApcWT+OX neurons, 459 from 8 
ApcPirc/++control neurons, and 362 from 9 ApcPirc/++OX neurons) for each neuron per experimental group.  e, 
Confocal images of mechanosensory nerve terminals in muscle spindles immunolabeled against VGluT1 
(green), Kv3.3 (red), and merged (yellow) illustrates protein expression levels and distribution in ApcPirc/++OX 
relative to ApcWT+control.  * indicates statistically significant differences between experimental groups as 
empirically derived from hierarchical Bayesian model (stan_glm). ** indicates PeBayesAdj<0.005 and fold-
change (FC) >1.5 using a Bayesian moderated linear fixed effects model. Data presented as mean±s.e.m 
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Figure 17. 
 Heat-map distribution of significantly differentially expressed genes specific to neuron neuronal 
excitability. Major voltage-gated, mechanically gated, TRP channels and ligand-gated and G-protein 
coupled receptors across experimental groups. Expression patterns of different sub-types channels and 
receptors were identified by empirical Bayesian moderated linear fixed effects models (columns are 
individual samples, heat-maps). (a) Sodium channel levels, (b) calcium channel levels, (c) chloride channel 
levels (d) potassium channel levels, (e) G-protein coupled receptors (GPCRs) levels, (f) ligand-gated 
channel levels, and (g) transient receptor potential (TRP) channel levels are plotted as heat-maps. Data row 
standardized (mean centered and s.d. normalized) to specific genes.  
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Figure 18. 
Kv3.3 immunostaining of proprioceptive sensory neurons receptor endings and cell bodies. a-d, 
Whole-mount staining and confocal axial projection of the preterminal axons and annulospiral receptor 
endings of proprioceptive sensory neurons showing merged and single channel images of Kv3.3 (red) and 
NF-H (green) in top row from: a, ApcWT+control rat; b, ApcPirc/++control; c, ApcWT+OX; d, and ApcPirc/++OX 
rats. Individual optical planes (from z-stack projection) of axial projection highlight fine three-dimensional 
structural distribution of merged and single channel images of Kv3.3 (bottom). Whole-mount staining and 
confocal axial projections of DRG neurons highlight expression of Kv3.3 in e, ApcWT+control rat; f, 










Kv3.3 Immunostaining of neuromuscular junction. Whole-mount staining and confocal axial projection of 
the neuromuscular junction showing merged images of Kv3.3 (red) and NF-H (green) from: a, ApcWT+control 
and b, ApcPirc/++OX rats.  
 
Summary 
This is the first evidence implicating Kv3.3 in the development of neuropathy and the first 
data, to our knowledge, demonstrating a channelopathy that persists long after treatment 
cessation. The capacity of Kv3.3 to drive fast spiking and to enhance transmitter release 
– processes that are required for mechanotransduction and spike encoding– suggests 
that this ion channel might provide both a potential novel mechanism for the dysfunction 
of mechanosensory neurons and a potential target for therapy.  
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Aim 3: Test the hypothesis that neuronal dysfunction depends 
on cancer-chemotherapy interaction. 
Introduction 
To test whether interaction we discovered at gene and protein levels was conserved at a 
functional neuron level in living animals, we tested whether APCPirc/+ mutants treated 
with OX express neuronal signaling dysfunction in vivo by examining the capacity of 
single proprioceptive neurons to respond to physiologically-relevant stimuli (Figure 21).   
Aim Specific Methods 
In vivo Intracellular Recording 
Dorsal rootlets positioned in continuity on bipolar recording electrodes were selected for 
sampling sensory neurons when they produced robust action potential activity in 
response to stretch of triceps surae muscles. Individual axons penetrated in these 
rootlets by glass micropipettes (~30 MΩ filled with 2 M K+ acetate) were selected for 
study when electrical stimulation of triceps surae nerves produced orthodromic action 
potentials that were readily resolvable and had conduction delay of <2ms. Continuous 
intracellular recordings from sensory neurons were acquired with Spike2 software 
(version 8.02). Sensory neurons were classified as Ia by their perfect entrainment to 1-s 
bouts of high-frequency, small-amplitude vibration (100Hz, 80 µm), pause in firing during 
rising twitch force response (muscle shortening), and by responding with an initial burst 
of high-frequency firing (>100 pulses per second (pps)) at the onset of muscle stretch 
(Vincent, Gabriel et al. 2017). Two stretch paradigms were used to characterize the firing 
responses of afferents to physiologically relevant mechanical stimuli. In both paradigms, 
triceps surae muscles were stretched by 3 mm from Lo (7% strain). Ramp-hold-release 
stretches tested afferent encoding of both fast dynamic (20mm/s, 47% strain rate) and 
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static stimuli; successive triplets of triangular stretch tested slow (4mm/s, 9% strain rate) 
dynamic and activity-dependent encoding in dynamic stretch known to be influenced by 
recent signaling history (Vincent, Gabriel et al. 2017). Strains and strain-rates fall within 
values expected for animals engaged in normal activities e.g. locomotion, and have 
been previously used in our lab (Vincent, Gabriel et al. 2017). 
Intracellular Recording Pre-Processing 
Intra-axonal recordings of action potentials together with records of muscle length and 
force were digitized (20 kHz) and were monitored online and stored on computer for later 
analysis with Spike2 and custom-written MATLAB scripts. From raw intracellular data of 
both paradigms, we extracted 31 measured and derived features (Figure 20) that 
provide a comprehensive quantification of neuronal signaling characteristics. We then 
categorized features into four broad clusters that represent functional features encoded 
by these neurons, containing sensitivity (Thr), dynamic (Dyn), static (Stat), and history-
dependent (Hx) signaling information. Figure 20 identifies and describes the measured 





List of Parameters used for Neurophysiological Analyses, related to Figures 2, 3 and Extended Data 
Figure 12. a, Measured and derived parameters were computed offline using custom written MATLAB 
scripts. Letters in the left column indicate the specific parameters included in analyses for each functional 
feature cluster. Thr: threshold (9 parameters); Dyn: dynamic (11 parameters); Stat: static (8 parameters); 
HxDep: history-dependent (1 parameter). For detailed experimental recording paradigms see Online 
Methods. b, Representative fast ramp-hold-release (3 mm at 20mm/s) trial from a proprioceptive neuron 
recorded from dorsal roots in in vivo electrophysiological experiments of a wild-type rat. c, Representative 
slow repeated ramp (3 mm at 4mm/s) trial from a proprioceptive neuron recorded from dorsal roots in in vivo 
electrophysiological experiments of a wild-type rat. Corresponding action potential trains and overlaid black 
circles indicate individual action potentials (spikes) and instantaneous firing rates (IFRs) of the responses. 
Dashed line marks the point of muscle stretch from background length (Lo) and indicates the starting point 
for threshold/sensitivity measurements. Boxes indicate dynamic (dark grey, 150 ms duration after stretch 
command onset) and static phases for analysis (light grey, 1 s duration after the dynamic phase) 
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Statistical Analysis of Intracellular Recordings  
Linear discriminant analysis (LDA) provided supervised dimensionality reduction for the 
multiple features of neuron signaling, in an attempt to find a linear combination of 
features that separated and characterized independent and combinatorial treatment 
effects. Data were first de-meaned, normalized to unit standard deviation, and tested by 
Bayesian one-way ANOVA (stan_glm) (Gabry and Goodrich 2018). The derived 
covariance matrix was then normalized by within-group, pooled covariance. The 
eigenvectors of that modified covariance matrix defined three canonical variables that 
characterized and separated the four treatment groups identified a priori as 
ApcWT+control, ApcWT+OX, ApcPirc/++control, and ApcPirc/++OX. LDA and 10-fold cross 
validation of model performance (repeated holdout method) was performed with the 
MASS (7.3-51.1) (Venables and Ripley 2002) library in the R environment (3.5.0) (Team 
2018). Individual features characterizing the firing responses of neurons sampled from 
multiple rats were tested for statistically significant differences with Bayesian one-way 
ANOVA (stan_glm). Descriptions of the general approach and detailed model 
construction and validation is below.   
Results 
Neuronal signaling is impaired 
Applying electrophysiological methods to rats in vivo, we recorded spiking activity from 
single mechanosensory neurons responding to naturalistic mechanical stimuli (Figure 
23). From these spiking responses, we collected 31 measured and derived parameters 
(average of four trials; n = 11 ApcWT+control, n=19 ApcWT+OX, n=20 ApcPirc/++control, n = 
10 ApcPirc/++OX; Figure 20) from which we extract four functional features encoded by 
these neurons, sensitivity, dynamic, static, and history-dependent signaling information 
(Figure 20). In ApcWT+control rats, we found that muscle stretch elicited the spiking 
 57 
expected from sensory neurons in normal animals (Vincent, Gabriel et al. 2017) and 
humans (Burke, Hagbarth et al. 1978), specifically high frequency initial bursting at 
stimulus onset, increasing dynamic firing during increasing stimulus, sustained static 
firing with slow accommodation during the hold phase of stretch (Figure 23b), and 
history-dependent reduction in spike number (Figure 22 and Figure 27h).  
Figure 21. 
Steps of In Vivo Electrophysiology Analysis. Data analysis flowchart depicts the multi-step approach 
applied for single neuron physiological analyses, inferences and downstream model validation. A detailed 
description of each step is available in the Methods Sections. Linear discriminant analysis, LDA.  
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Figure 22. 
 Neuronal signaling responses to slow and fast naturalistic stimulus. related to Figures 5, 6. a, 
Representative fast ramp-hold-release (left, 3 mm at 20mm/s) and slow repeated ramp (right, 3 mm at 
4mm/s) trial from a proprioceptive neuron recorded from dorsal roots in in vivo electrophysiological 
experiments of an ApcWT+control (grey) and ApcPirc/++OX rat (purple). Corresponding action potential trains 
and overlaid black circles indicate individual action potentials (spikes) and IFRs (instantaneous firing rates) 
of the responses. Dashed line marks the point of muscle stretch from background length (Lo) and indicates 
the starting point for threshold/sensitivity measurements. Boxes indicate dynamic (dark grey, 150 ms 
duration after stretch command onset) and static phases for analysis (light grey, 1 s duration after the 









Mechanosensory signal degradation exacerbated by the cancer–chemotherapy interaction. a, 
Schematic of experimental approach for in vivo recordings centrally from intact mechanosensory neurons 
firing action potentials in response to fast (20mm/s) and slow (4mm/s) naturalistic mechanical stimuli 
delivered in the periphery. b, Representative cases of spiking activity in ApcWT+control, ApcWT+OX, 
ApcPirc/++control, and ApcPirc/++OX as a measure of sensory encoding. Black circles plot instantaneous firing 
rates (pps) of corresponding spike (action potential) intervals. Dashed vertical line marks onset of muscle 
stretch (3mm from resting length (Lo)) shown in bottom trace divided into dynamic and static phases by dark 
grey (150 ms duration after stretch command onset) and light grey (1 s duration after the dynamic phase) 
bars. c, Neuronal spiking parameters (n=31 averaged from four trials in each neuron, four shown from fast 
ramp stimulus) representing different features of sensory stimulus (ApcWT+control (n = 11), ApcWT+OX (n = 
19), ApcPirc/++control (n = 20) and ApcPirc/++OX (n = 10)): mean initial burst frequency (pps) signaling stretch 
onset; the number of spikes during dynamic sensory stimulation (shown as a dark grey bar in b); the number 
of spikes during static sensory stimulation (shown as a light grey bar in b); sensitivity assessed as the 
inverse of latency to stimulus detection (ms-1), i.e. lower sensitivity corresponds to longer latency and higher 
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threshold. d, Confocal image of a neurofilament heavy-chain (NEFH, in green) with immunolabeling of the 
terminal axon and receptor structure in ApcWT+control, ApcWT+OX, ApcPirc/++control, and ApcPirc/++OX rats. 
Scale bar, 15 μm. * indicates statistically significant differences between experimental groups as empirically 
derived from hierarchical Bayesian model (stan_glm): 95% highest density intervals do not overlap between 
groupwise contrasts. Data presented as mean±s.e.m. 
We next tested whether ApcPirc/+ or OX treatment alone induce signaling dysfunction. 
Although we find transcriptional dysregulation in ApcPirc/++control Figure 6c and Figure 
9a), we found a remarkable degree of concordance with signaling in ApcWT+control 
(Figure 23b). ApcPirc/++control neuronal signaling displayed comparable sensitivity to 
stimuli and showed similar static behavior across all neurons (n = 20; Figure 23b,c) as 
the ApcWT+control. We then found that OX treatment of ApcWT rats induced mild 
signaling deficits that were less pronounced, occurred in a small proportion of neurons 
(5/19), and were primarily restricted to sensitivity functional clusters (Figure 23b,c and 
Figure 24d), validating our previous findings of restricted deficits (to single signaling 
parameters) observed in a different strain of healthy rats treated with OX alone (Vincent, 




LD1 analysis of all neuronal parameters. a, Confusion matrix illustrates the results of 10-fold cross 
validation of LDA model performance (repeated holdout method) that achieved overall 94.7% classification 
accuracy (posterior prediction check). Table values represent the sum of out-of-sample cross validation 
predictions (row) against true class assignment (column) b, Histogram plot, mean values of LD1 scores 
(Figure 27) for each group were compared with hierarchical Bayesian ANOVA model. Asterisk indicate 
statistically significant differences between experimental groups in hierarchical Bayesian ANOVA, (*) 
indicates 95% highest density intervals (HDI) do not overlap between groupwise contrasts. c, Vectors 
represent the magnitude and direction of the independent and combinatorial effects of cancer and/or 
chemotherapy. d, Parameters (n =31, middle) and respective discriminant coefficients weights with the 
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interaction-specific LD1, were regrouped into functional feature clusters (left). Histogram plots report mean 
values for individual parameters (right, a-l) with significant contribution to LD1 loading. Cross symbol indicate 
parameters are included in Figure 23 and Figure 27. Analyzed from ApcWT+control (n = 11), ApcWT+OX (n = 
19), ApcPirc/++control (n = 20) and ApcPirc/++OX (n = 10) neurons. 
In contrast to the observations in ApcWT+control, ApcWT+OX, or ApcPirc/++control rats, we 
found drastically impaired neuronal signaling in ApcPirc/++OX rats (Figure 23b). High 
frequency initial bursting was attenuated four-fold and sensitivity to stimuli was reduced 
by three-fold at both high (Figure 24d) and low velocity stretch (Figure 22, Figure 24d). 
During dynamic stimuli, we found marked reduction in the number of spikes over both 
stretch conditions (Figure 23c). Neurons in ApcPirc/++OX rats also failed to sustain firing 
(Figure 23b). In addition, we observed fewer spikes (Figure 23c) during rapid 
accommodation immediately preceding signal deletion, despite constant stimulus (Figure 
23b). We then simulated naturalistic compensation by subjecting ApcPirc/++OX neurons to 
repeated trials at 1, 2, and 3x background stimulus (Lo strain) intensity, which failed to 
completely rescue signaling back to ApcWT+control levels (Figure 25b, c, d). These data 
are the first to directly demonstrate a damaging functional interaction between the 
systemic effects of cancer and chemotherapy in sensory neurons in a living animal. 
While validating our previous findings of signaling deficits in chemotherapy alone 
(Vincent, Wieczerzak et al. 2016), these data indicate that restrictive signaling deficits 
induced by chemotherapy or cancer alone were insufficient to reproduce the magnitude, 






Effects of physiologic compensation. a, b, Representative fast ramp-hold-release (left, 3 mm at 20mm/s) 
trial from a proprioceptive neuron recorded from dorsal roots in in vivo electrophysiological experiments of a 
ApcWT+control (grey a) and ApcPirc/++OX rat (purple b). Corresponding action potential trains and overlaid 
black circles indicate individual action potentials (spikes) and IFRs (instantaneous firing rates) of the 
responses. Dashed line marks the point of muscle stretch from background length (Lo) and indicates the 
starting point for threshold/sensitivity measurements. Boxes indicate dynamic (dark grey, 150 ms duration 
after stretch command onset) and static phases for analysis (light grey, 1 s duration after the dynamic 
phase). Stretch evoked (3mm) responses recorded from replicate trials at 1, 2, and 3x Lo for Apc
WT+control 
(a) and ApcPirc/++OX (b). c, Raster plots of stretch evoked (3mm) responses from representative neurons in 
control (right) and ApcPirc/++OX (left) neurons recorded from repeated trials (4 trials) at 1, 2, and 3x 
background stimulus (Lo strain) intensity. Frequency histograms show cumulative distributions across 4 
trials. d, Overlaid interval histogram (four trials per neuron at each of three stimulus intensities shows 
population shift. Inset show non-overlaid interval histograms for clarity. * indicates statistically significant 
differences between experimental groups as empirically derived from hierarchical Bayesian model 
(stan_glm): 95% highest density intervals do not overlap between groupwsie contrasts.  
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Dysfunction does not depend on degeneration  
We next tested whether the impaired neuronal signaling of ApcPirc/++OX neurons might 
be explained by dying-back degeneration of sensory nerve terminals. While the 
underlying mechanisms for chemotherapy induced neuropathy are not understood, 
current opinion identifies ‘dying-back’ axon degeneration as a major pathology in this 
disorder (Park, Goldstein et al. 2013; Fukuda, Li et al. 2017). Blinded reviewers 
assessed the structural integrity of sensory afferents and receptor endings 
immunolabeled against neurofilament protein (NEFH) (Carrasco, Vincent et al. 2017). 
We then tested for functional evidence of degeneration by comparing differences in 
conduction delays, a physical measure of nerve degeneration that is used clinically 
(Burakgazi, Messersmith et al. 2011).  Neither histological observation of sensory 
afferents and receptors (Figure 23d) nor axon conduction tests (Figure 26) revealed 
evidence of dying-back degeneration of sensory nerve terminals (ApcPirc/++OX: 
1.41±0.13ms, n=10. ApcWT+control: 1.52±0.14ms, n=11, Figure 26). Our findings 
demonstrate that transcriptional changes we observed for some markers of nerve 
degeneration (Figure 10) were insufficient to yield nerve degeneration. While our results 
indicate selective resistance of mechanosensory neurons in ApcPirc/++OX rats, they are in 
line with the inconsistency of physical evidence for nerve degeneration reported in 
clinical studies (Burakgazi, Messersmith et al. 2011).  Furthermore, the ability of muscle 
vibration to entrain firing of these neurons in all treatment groups as they do in 
ApcWT+control rats further refutes the existence of degeneration’s necessity in signaling 
disorders (Figure 26). Overall, our findings suggest that the structure and core ability of 
mechanosensory neurons to produce action potentials remain unimpaired by 




Cancer and chemotherapy interaction does not lead to electrophysiological evidence of 
degeneration. a, raw intracellular record from control and ApcPirc/++OX neurons shows derivation of 
conduction delay (ms). Conduction delay is calculated by subtracting the time from electrical stimulus to 
electrically evoked action potential. b, Mean conduction delay (ms) computed for all neurons as a measure 
of axonal demyelination were analyzed from ApcWT+control (n = 11), ApcWT+OX (n = 19), ApcPirc/++control (n 
= 20) and ApcPirc/++OX (n = 10) neurons with hierarchical Bayesian ANOVA model. ns, no significant 
difference. c & d, Two representative stretch evoked responses of two sensory neurons (ApcPirc/++OX) 
recorded from dorsal roots in in vivo electrophysiological experiments with corresponding action potential 
trains. Overlaid black circles are IFRs of the responses. Insets show expanded view from (d) in a trial 
without (d1) and with (d2) superimposed vibration stimulus. 
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Neuronal dysfunction depends on cancer-chemotherapy interaction 
Data presented in Figure 23 suggests damaging cancer-chemotherapy interactions are 
conserved in vivo and have consequences in sensory function. In order to assess the 
extent of interaction quantitatively, we took an unbiased statistical approach by 
subjecting all neurons (n=60, 240 total trials) from all experimental groups to a machine 
learning algorithm (linear discriminant (LD) analysis). Our approach reduced complex 
feature space into canonical variables giving us a high-level understanding of where 
interaction emerges, without biased feature selection a priori. Our analysis yielded three 
canonical variables (Figure 27a) that achieved overall 94.7% classification accuracy 
(Figure 24a). We then visualized neuronal signaling in the new 3D composite space 
created by LD1-3 (Figure 27a). By projecting high dimensional parameter and feature 
data onto a simplified 3D canonical space, statistically significant non-linear interaction 
between cancer and chemotherapy clearly emerged in the first dimension (LD1; 54.23% 
proportion of variance; Figure 27a and Figure 24b). Notably, dysfunction in LD1 induced 
by the cancer—chemotherapy interaction occurred in the opposite direction to that 
predicted by independent effects, and its magnitude was amplified greater than their 
sum (Figure 27a and Figure 24b, c). To test the statistical significance of the cancer—
chemotherapy interaction, we conducted Bayesian model comparison with full factorial 
and all restricted models using leave-one-out cross validation. We then quantified and 
validated each model’s predictive performance by computing the expected log predictive 
densities (ELPD;  measure of a model’s out-of-sample predictive accuracy in Figure 27b-
e) (Vehtari, Gelman et al. 2017).  We found decisive evidence in favor of a model 
including a cancer–chemotherapy interaction predictor (ELPD diff ≥ 48 SE <8.1; Figure 
27e). Moreover, our data and generative modeling conclude that codependent 
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interaction (Figure 27b-d) is necessary to accurately and reliability reproduce clinically 
relevant neuronal signaling deficits observed in ApcPirc/++OX rats (Figure 27e).  
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Figure 27. 
Cancer-chemotherapy codependence exacerbates sensory dysfunction beyond that predicted by 
cancer or chemotherapy alone. a, Neuronal spiking parameters (n=31, averaged from four trials, from 
each neuron (n=60)) representing different features of sensory stimuli were subjected to linear discriminant 
(LD) analysis. Neuronal signaling was visualized in the new 3D composite space created by LD1-3.  3D 
ellipsoids enclosing 68% of data were computed with least-squares elliptical fitting to emphasize differences 
between control and ApcPirc/++OX neurons. Effects of independent (OX or ApcPirc/+) and combinatorial 
(ApcPirc/++OX) treatment are indicated by curved arrows. b-e, The hierarchical Bayesian model used to test 
for significant group differences in LD1 scores reconfigured to operate in a predictive fashion. Predictors 
included in each model are listed to the right of each plot. Generative models in (b-d) utilizing one (b,c) or 
both independent (d) predictor(s), i.e. cancer (ApcPirc/+) or chemotherapy (OX) for posterior prediction . The 
generative model in (e) utilizes both independent predictors and an interaction term for posterior prediction. 
Grey lines in b-e represent 500 novel (generative) samples drawn from the posterior distributions. Black 
lines illustrate experimentally observed mean LD1 score. Predictive accuracy was measured by calculating 
expected log predictive density (ELPD) for each model and benchmarked off of the highest performing 
model. Delta ELPD (triangular symbol) indicates difference from optimal model. Negative models represent 
worse predictive performance. f, Sensitivity assessed as the inverse of latency to stimulus detection (mm-1), 
i.e. lower sensitivity corresponds to longer latency and higher threshold. g, Peak firing rate (pps) achieved 
during the dynamic sensory stimulus (shown as dark grey bar in Figure 23b). h, change in dynamic spike 
number in successive, slow stretch dynamic sensory stimulus (see Methods and Figure 20) and mean firing 
rate (pps) achieved during the static sensory stimulus (shown as light grey bar in Figure 23b). Recordings 
were analyzed from ApcWT+control (n = 11), ApcWT+OX (n = 19), ApcPirc/++control (n = 20) and ApcPirc/++OX 
(n = 10) in b-g, * indicates statistically significant differences between experimental groups as empirically 
derived from hierarchical Bayesian model (stan_glm). Grey arrows in f-h indicate direction and significant 
differences from ApcWT+control predicted from the linear sum of the independent effects of ApcWT+OX and 
ApcPirc/++control groups. Black arrows indicate experimentally observed effects of their combination.  Circles 
with slashes indicated no difference predicted for ApcWT+OX group and ApcPirc/++control groups. Data 
presented as mean ± s.e.m. 
Having determined the significance of an interactive effect, we then asked which 
functional clusters are highly enriched in LD1.  By examining the discriminant function 
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coefficients, we found that static signaling and sensitivity functional clusters represent a 
large portion of the explained variance in LD1. These findings suggest the sensitivity and 
static signaling clusters are most susceptible to codependent neuropathy (Figure 24d). 
While dynamic signaling provided relatively modest contributions to LD1 (lower 
coefficient weights in Figure 24d), examining the parameter level data allowed us to 
discover the expression of distinct classes of interactions. Independently, OX and 
ApcPirc/+ induce highly conserved (87.5%) opposing effects exclusively within the dynamic 
functional cluster. We consistently found that ApcPirc/+ mutation increased and OX 
treatment decreased dynamic firing (Figure 27g). This led us to predict that their 
combination would nullify dysfunction and approximate ApcWT+control signaling. Instead, 
we observed opposing interactions that resulted in drastic reduction in dynamic firing 
properties. By contrast, for history-dependent functional clusters, we found that cancer–
chemotherapy interaction emerged exclusively in ApcPirc/++OX neurons, since neither 
ApcWT+OX nor ApcPirc/++control neurons were disrupted (Figure 27h). 
Summary 
Taken together, we found that 58% of the neuronal signaling parameters in ApcPirc/++OX 
rats showed high-confidence interaction effects, in that those deficits were greater than 
those observed in either ApcWT+OX nor ApcPirc/++control rats. Our findings demonstrate 
that complex systemic perturbations of chemotherapy and cancer result in synergistic 
interactions for sensitivity signaling characteristics, i.e. where cancer and chemotherapy 
impart influence in the same direction.  (Figure 27f), opposing interactions for peak firing 
rate during dynamic signaling, i.e. where cancer and chemotherapy impart influence in 
the opposite directions.  (Figure 27g), and emergent interactions for history dependent 
and static signaling characteristics, i.e. where cancer and chemotherapy independently 
impart no influence but their combination has effects (Figure 27h). In summary, 
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ApcPirc/++OX rats express widespread neuronal signaling dysfunction that targets all 
functional clusters, was independent of structural or physiologically detected 
degeneration and were not fully accounted for by a global decrease in sensitivity.  
Aim 4: Test the hypothesis that down regulated Kv3.3 
expression is sufficient to reproduce neuronal dysfunction 
observed following chronic chemotherapy treatment of cancer. 
Introduction  
To test the sufficiency of down-regulated Kv3.3 receptor (annulospinal) currents to 
reproduce ApcPirc/++OX neuronal dysfunction, we developed a novel biophysical model of 
rat muscle-spindle based on the known region-specific channel composition of rat 
muscle spindles (Bewick and Banks 2015; Woo, Lukacs et al. 2015; Carrasco, Vincent 
et al. 2017) and newly discovered Kv3.3 channel.   
Aim Specific Methods 
Biophysical modeling of muscle spindle firing 
In the NEURON 7.6 simulation environment, we developed a novel biophysical model of 
rat muscle-spindle based on the known region-specific channel composition of rat 
muscle spindles (Bewick and Banks 2015; Woo, Lukacs et al. 2015; Carrasco, Vincent 
et al. 2017) and newly discovered Kv3.3 channel.  The model was designed to simulate 
the behavior of muscle spindles from ApcWT+control animals as they respond to identical 
stimulations to those presented in vivo. 
We modeled a single branch of the Ia fiber system with terminal, preterminal axon, 
heminode (first node), and subsequent four myelin and node segments. Figure 28 shows 
channels distributions for different compartments based on available information. When 
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channels are found in more than one location, their densities are higher on the nodes 
and paranodes than elsewhere.  We also included an activating Ca channel that is built 
into the modeled SK channels.  The mechano-sensitive channel is activated by tension 
in the receptor area and also has a slow tension-dependent inactivation. 
We modelled mechanotransduction by dividing the spindle into a polar (intrafusal 
muscle) and non-polar region (sensory terminal).  The non-polar region is purely elastic 
whereas the tension developed in the polar regions shows a non-linear relation between 
tension and muscle length and velocity analogous to extrafusal muscle as described by 
(Hasan 1983). We derived the following equation relating sensory terminal length (m) 
two muscle length (x) and velocity as described by Hasan 1983 with the exception of not 
directly translating this function into spindle firing rate as originally described. Instead we 
model the transformation of stretch-evoked mechanical stimuli to conductance 














where a (0.0003 (mm/ms)), b (250) and c (-15 (mm)) are constants.  Constant a is 
inversely related to the strength of the velocity effect, b reflects the relative compliance 
of the two regions and c represents the slack length of the polar regions (Hasan 1983).  
Additionally, we model the max conductance (gbar) of the mechanotransduction region 
(gbar=0.01 (MWt/cm2)), the slope of Boltzman equation specifying sensory length (Lslp) 
to conductance (Lslp = 0.05 (mm)), half activation point (Lhalf = 0.1 (mm)), and 
membrane time constant (taum = 5 (ms)). Along with the modeled mechanotransduction 




Conductances Parameters for Biophysical Modeling. Breakdown of maximum conductances for each of 
the four modelled regions for both ApcWT+control and ApcPirc/++OX animals. Parameters labelled in red 
indicate experimentally altered values in ApcPirc/++OX.  
Terminal ApcWT+control ApcPirc/++OX 
 gbar gbar 
Na1.6 200pS/µm2 200pS/µm2 
Nav1.7 200pS/µm2 200pS/µm2 
Nav1.8 0.001MWt/cm2 0.001MWt/cm2 
Na1.1 200pS/µm2 200pS/µm2 
KCNQ 0.004MWt/cm2 0.006MWt/cm2 




SK(mAHP) 0.0005 S/cm2 0.0005 S/cm2 
Ca2+lowThr 5e-5 S/cm
2 5e-5 S/cm2 
 
Paranode ApcWT+control ApcPirc/++OX 
 gbar gbar 
Nav1.8 0.001MWt/cm2 0.001MWt/cm2 
Kv3.3 0.008S/cm2 0.000S/cm2 
Kv1.1 0.008S/cm2 0.008S/cm2 
 
Pre-Terminal ApcWT+control ApcPirc/++OX 
 gbar gbar 
Na1.6 200pS/µm2 200pS/µm2 
Nav1.7 200pS/µm2 200pS/µm2 
Na1.1 200pS/µm2 200pS/µm2 
KCNQ 0.004MWt/cm2 0.006MWt/cm2 




Ca2+lowThr 5e-5 S/cm2 5e-5 S/cm2 
 
Nodes ApcWT+control ApcPirc/++OX 
 gbar gbar 
Na1.6 200pS/µm2 200pS/µm2 
Nav1.7 200pS/µm2 200pS/µm2 
KCNQ 0.004MWt/cm2 0.006MWt/cm2 
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Figure 28. 
Anatomical distribution of ion channel constituents of biophysical computational model of muscle 
spindle. a, Model of one branch of the Ia fiber system with terminal, preterminal axon, first node 
(heminode), and subsequent node-myelin pairs. Model of identifies the spatial distribution of ion channels in 
muscle spindle Ia primary ending. The intrafusal muscle fiber (red) is wrapped by an annulospiral ending 
(green) and a preterminal axon that extends unmyelinated from the terminal to the heminode (pink) followed 
by a myelinated axon. Dotted-boxes represent specific regional distributions believed to underlie specific 
functional characteristics of neuronal signaling e.g. mechanotransduction, signal amplification, encoding, 
and autogenic feedback. b, Example of ApcWT+control and ApcPirc/++OX response from the biophysical 
spindle model (red) overlaying experimental ApcWT+control and ApcPirc/++OX data. Figure shows the mean 
instantaneous firing rates. Dashed vertical line marks onset of muscle stretch (3mm) from resting length (Lo). 
Dynamic and static phases of naturalistic stimuli indicated by dark grey (150ms duration after stretch 




Biophysical model of muscle spindle reproduces canonical firing behavior 
The model was developed and implemented in NEURON 7.6 to simulate the behavior of 
muscle spindles from ApcWT+control animals and those treated with ApcPirc/++OX as they 
respond to identical stimulations to those presented in vivo (Methods). The 
ApcWT+control simulation (Figure 28b) reproduced experimental firing behaviors over 
dynamic and static simulated length change stimuli i.e., linearly increasing firing rates as 
length changes over constant velocity and slow firing rate accommodate (decay) as 
length stimuli is help at a constant length.  
Down regulating Kv3.3 is sufficient to explain key features of firing dysfunction 
We then modelled ApcPirc/++OX muscle spindles by systematically eliminating Kv3.3 
expression on the receptor as was seen the above immunohistochemical analyses 
(section 1.3.2.2).  ApcPirc/++OX simulation (Figure 28b) reproduced certain features of in 
vivo data and not others. Notably, through this targeted ionic perturbation we eliminated 
static firing throughout the hold phase and blunted the dynamic firing rates whereas no 
change in threshold was observed.  
Summary 
Collectively, the results of computer simulations indicate that a reduction in Kv3.3 
expression, as observed experimentally, is sufficient to reproduce many of the firing 
defects in mechanosensory neurons and suggest this as one candidate biophysical 
mechanism that may be directly or indirectly targeted by the cancer-chemotherapy 
interaction. Moreover, the failure of simulated Kv3.3 down-regulation to reproduce 
defects in threshold provides strong evidence that additional biophysical mechanisms 
are present.   For example, up-regulated gene KCNN2 that encodes SK2 (Figure 17) 
recently discovery in mammalian muscle spindle receptors may provide the additional 
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Ca2+ gated K+ current to increase threshold. Alternatively, and increased Kv1.1 or KCNQ 
could lead to a comparable change in threshold. Because both Kv1.1 and KNCQ 
channels have low voltage thresholds, small increases in expression, that could be 
masked by our bulk transcriptional profiling, of either channel could increase spindle 
threshold.  
Aim 5: Test the hypothesis that cancer exacerbates 
sensorimotor dysfunction after chronic chemotherapy treatment 
in an awake behaving animal.    
Introduction 
To test the behavioral consequences of the cancer-chemotherapy interaction, we 
evaluated ApcPirc/++ OX rats’ performance in horizontal random rung ladder walking.  
This precise walking task overbalances performance on proprioceptive function (Metz 
and Whishaw 2002; Metz and Whishaw 2009) since rats move forward with vision 
directed forward. Under these experimental conditions, success relies on proprioceptive 
function that assists with foot placement on rungs that pass out of sight.  
Aim Specific Methods 
Behavioral analysis 
We used the ladder rung walking task as a validated outcome to detect and describe 
sensorimotor deficits (Metz and Whishaw 2002; Metz and Whishaw 2009). The ladder 
rung apparatus was built as previously described (Metz and Whishaw 2002). Secure 
hind foot placement was assessed using the seven-category scale scoring system 
introduced by (Metz and Whishaw 2002; Metz and Whishaw 2009) with modifications as 
to not distinguish whether or not an error was associated with a deep fall. The total 
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number of errors in forelimb (e.g. Figure 29d) and hindlimb (e.g. Figure 29e) placement 
was calculated and the mean error/step ratio was calculated per animal and represented 
as percent of error where an increase in the number of errors/steps corresponds to a 
decrease in secure foot placement of the hind and/or fore foot. 
Results 
Behavioral dysfunction exacerbated by cancer-chemotherapy interaction  
ApcWT+control and ApcPirc/++control rats achieved a high incidence of rear and fore foot 
placement, when walking on the rungs of a uneven horizontal ladder, with a foot-drop 
error rate of only 2.4% (±2.7% SD, 6 animals; Figure 29a and Movie S1) and 2.5% 
respectively (±2.9% SD, 4 animals; Figure 29a and Movie S1). In contrast, ApcPirc/++ OX 
exhibited a 19.2% foot-drop error rate (±5.6% SD, 7 animals; hierarchical Bayesian 
model (stan_glm) vs. ApcWT+control and ApcPirc/++control; Figure 29a and Movie S2). 
ApcPirc/++ OX error rates significantly exceeded our previous findings following OX 
treatment alone (Wistar+OX) of 8.4% (±3.1% SD, 7 animals; hierarchical Bayesian 
model (stan_glm) vs ApcPirc/++ OX; Figure 29). Independent analysis of fore- (Figure 29b) 
and hind-foot (Figure 29c) error rates revealed that skilled motor behavior degradation 
was significantly exacerbated by the emergence of fore-limb errors (10.4%±3.9SD) not 
present in ApcWT+control (0%), ApcPirc/++control (2.3%±2.8SD), or Wistar+OX (0%; 








Behavioral dysfunction exacerbated by cancer-chemotherapy interaction. a, Total gait errors as 
measured by secure fore- and hindfoot placement was scored by errors/step cycle during ladder rung 
walking. Recordings were analyzed from ApcWT+control (n = 6), Wistar+OX (n = 7), ApcPirc/++control (n = 4) 
and ApcPirc/++OX (n = 7) animals. b-c, indicate the contributions of fore- (b) and hindlimb (c) errors to total 
error rates. d, Photograph shows left forelimb slip in double image (simultaneous side and underneath 
views) of ApcPirc/++OX rat walking on ladder rungs. e, Photograph shows left hind limb slip in double image 
(simultaneous side and underneath views) of ApcPirc/++OX rat walking on ladder rungs (representative cases 
of entire ladder rung walking trials can be viewed at Movie S1 and Movie S2 for ApcWT+control and 
ApcPirc/++OX rats respectively). * indicates statistically significant differences between experimental groups 
as empirically derived from hierarchical Bayesian model (stan_glm): 95% highest density intervals do not 




Our data reveal that proprioceptive sensory input from muscle spindles ensures limb 
placement accuracy in a skilled motor behavioral task. Moreover, discovering that 
cancer-chemotherapy interaction results in the emergence of novel forelimb deficits 
(Figure 29b, d) typically not observed in this challenge to hindlimb capacities (Figure 
29c, e) provides further evidence that exacerbation effects are unpredicted from studying 
chemotherapy alone.  
 
Project 1: Discussion  
Here we present original evidence that cancer transforms the nature and magnitude of 
neuropathy induced by chemotherapy alone.  Our preclinical study of rats is the first to 
compare the neuropathic effects of chemotherapy and cancer, both independently and in 
combination, currently impractical in human study.  These comparisons for global 
transcriptional analysis of sensory neurons in dorsal root ganglia revealed dysregulation 
of genes uniquely induced, amplified or suppressed by the combination of cancer and 
chemotherapy.  Codependence was conserved as impaired spike encoding of 
mechanosensory stimuli and novel ion channelopathy.   
Our transcription analyses expose two potential targets for treating sensorimotor 
disorders among the debilitating patient symptoms that persist following treatment of 
various cancers with platinum-based compounds and other antineoplastic agents, e.g. 
taxanes.  Patients display deficits in the spatiotemporal parameters (speed and stride) of 
walking gait, in control of posture, and in balance relying on proprioception (Marshall, 
Zipp et al. 2017; Monfort, Pan et al. 2019). Acknowledging that these disabilities may 
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arise from a variety of lesions in the nervous system, the deficits we observe here at the 
receptor origin of detection and encoding of muscle mechanics would necessarily impair 
movements and postures and cannot be fully compensated by other senses, e.g. vision.  
Furthermore, signaling by mechanosensory neurons in rats closely resembles that in 
human (Burke, Hagbarth et al. 1978).  For these reasons, we assign special attention to 
depressed signaling by muscle spindles and to the associated decrease in expression of 
the voltage-gated ion channel Kv3.3 and its gene Kcnc3. Kv3 channels play important 
role in attaining and maintaining high neuronal firing rates. Unique biophysical 
properties, e.g. high activation threshold, rapid activation, and deactivation kinetics, 
allow neurons that express Kv3 channels to quickly repolarize without compromising the 
inward current or Nav channels reactivation (Rudy and McBain 2001; Kaczmarek and 
Zhang 2017; Gu, Servello et al. 2018). Reports that Kcnc3 gene knock out impairs firing 
responses of neurons (Akemann and Knöpfel 2006; Espinosa, Torres-Vega et al. 2008) 
and results in ataxia (Figueroa, Minassian et al. 2010) promote this gene and its ion 
channel as potential contributors to signaling deficits observed in the present study.  
While our biophysical modelling provides evidence that Kv3.3 is sufficient to explain 
certain neuronal signaling deficit, we are uncertain about the necessity of Kv3.3 
channelopathy to explain the full suite of deficient mechanosensory signaling in cancer 
treated by chemotherapy.  Uncertainty arises in part, because comprehensive 
understanding of the molecular mechanisms underlying the function of these sensory 
neurons is lacking, although advanced by our discovery of Kv3.3 in mechanoreceptors of 
healthy animals.  Another candidate target for treating sensorimotor disorders is the 
inflammatory signaling molecule IL6, shown here to express large increases in both 
gene and protein expression.  As a result of its effect in suppressing neuronal firing 
behavior (Nelson, Ur et al. 2002) IL6 has the potential to explain decreased signaling by 
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mechanosensory neurons.  We identify both Kv3.3 and IL6, therefore, as targets worthy 
of testing for their potential value in treating movement disorders.  Additional points of 
interaction likely exist, which remain either undiscussed (e.g. FosB) or potentially 
masked due to transcriptional profiling of DRG’s that may result in variable differential 
expression across heterogenous cell types.  
Muscle proprioceptors (Group Ia) provide invaluable sensory feedback to control 
movement (Prochazka and Ellaway 2012; Proske and Gandevia 2012), make rapid 
adjustments to unexpected perturbations (Nichols, Cope et al. 1999; Shemmell, Krutky 
et al. 2010), and preserve an internal representation of the body’s interaction with the 
environment (Ivanenko, Dominici et al. 2011). It seems to reason then that disruption in 
sensory encoding is a plausible model to explain the severely compromised ability to 
carry out precision ladder walking (Abelew, Miller et al. 2000; Sghirlanzoni, Pareyson et 
al. 2005).  We observed abnormal sensorimotor behavior characterized as difficulty with 
achieving proper limb placement in ApcPirc/++OX rats. Deficits were significantly greater 
than those previously observed in our lab from animals treated with OX alone. This 
observation further supports a link to altered proprioceptor signaling while also 
suggesting that the magnitude of signaling deficits might contribute to the magnitude of 
sensorimotor deficits, as evidenced by the emergence of forelimb errors that coincide 
with additional exacerbated signaling deficits. Data obtained in ApcPirc/++ OX rats were in 
agreement with previous results observed in animals without functional spindles (Egr3 
mutants) (Akay, Tourtellotte et al. 2014), indicating that the loss of sensory feedback 
from muscle spindles following cancer treatment may be sufficient to explain 
sensorimotor deficits experienced by cancer survivors.  
The emergence of forelimb errors might be explained by greater signaling impairment, 
i.e. lost sensitivity to stimuli and reduced dynamic response, in addition to the previously 
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described impaired static responsiveness. This necessarily results in larger information 
loss that may not be able to be compensated by vision or the CNS learning a new 
representation of the corrupt information. Stated another way, while the forelimbs are in 
the line of site for this task (ladder rung walking), the extent of sensory information loss 
may result in such decompensated (e.g. fragile) motor performance that even tasks that 
can rely on another feedback source, e.g. vision, can suffer. In addition, shifting 
dependence of feedback away from proprioceptive signals, that can operate on the scale 
of 10s of milliseconds, onto visual systems that operate on the scale of 100s of 
milliseconds imparts addition feedback delay that can accentuate errors that occur 
during the rapid movements required to complete the ladder rung walking task.  
Another contributor to the emergence of forelimb errors when cancer and chemotherapy 
interact might be differences in spinal circuitry and their interaction with corrupt sensory 
feedback. It is well documented that forelimbs and hindlimbs are controlled by 
functionally and anatomically distinct spinal circuits (Ballion, Morin et al. 2001; Juvin, 
Simmers et al. 2005; Frigon 2017). Various experimental preparations showing the 
forelimbs and hindlimbs can be physically and/or functionally uncoupled suggests that 
their responses to perturbations, e.g. chemotherapy alone or cancer and chemotherapy, 
might also be uncoupled(Ballion, Morin et al. 2001; Juvin, Simmers et al. 2005). This 
latter suggestion highlights the possibility that the signaling deficits identified in our 
previous reports (Vincent, Wieczerzak et al. 2016) could have been restricted to the 
hindlimb alone and it is not until the extent of the systemic perturbation was large 
enough, e.g. due to the addition of cancer that forelimb sensorimotor control faltered.   
Our study, being restricted to a single time point following chemotherapy, does not 
assess the stability of potential treatment targets that emerge from codependent 
neuropathy.   It is reasonable to expect, however, that the codependence undergoes 
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dynamic change.  Cancer, presumably also its associated systemic effects, undergoes 
complex progression as subpopulations of cancer cells differentially resist, adapt, or 
succumb to chemotherapy.  Moreover, biological systems themselves initiate dynamic 
responses to perturbations.  In the nervous system, homeostatic regulation initiates 
compensatory mechanisms to offset perturbations in neuronal excitability (Waxman and 
Zamponi 2014).  It is thought provoking in this regard to consider the possibility that the 
chronic hypoexcitability which follows the acute hyperexcitability (Cavaletti and Marmiroli 
2010; Park, Goldstein et al. 2013) that develops during chemotherapy reflects the 
actions of a dysregulated compensatory mechanism.  Understanding these non-linear 
interactions processes and their effects on potential treatment are both challenging and 
necessary for developing effective cancer treatment.  
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CHAPTER 4. PROJECT 2 
Project 2 is based on a single manuscript:  
1. Housley, S. N., Nardelli, P, and Cope, T. C. (2019). Mechanosensory encoding 
and neural decoding of musculoskeletal dynamics impaired following cancer 
treatment. (in preparation) 
Introduction 
Chemotherapy induced neuropathy (CIN) comprises a constellation of debilitating 
neurological disorders including sensorimotor impairments severe enough to persist long 
into disease free survival (Quasthoff and Hartung 2002; Cavaletti and Marmiroli 2010; 
Alcindor and Beauger 2011; Seretny, Currie et al. 2014; Sisignano, Baron et al. 2014; 
Stone and DeAngelis 2016). CIN reduces quality of life for many patients and can limit 
antineoplastic treatment, complicating its utility (Cavaletti and Marmiroli 2010; Alcindor 
and Beauger 2011; Stone and DeAngelis 2016). Despite intense pursuit, clinical trials 
founded on preclinical studies in animals without cancer (Currie, Angel-Scott et al. 
2018), have largely failed to deliver effective treatment for and/or prevention of CIN 
(Hershman, Lacchetti et al. 2014).   
This fundamental gap in understanding of CIN pathophysiology led us to test, in 
Project 1, whether clinically relevant CIN depends on codependence between cancer 
and chemotherapy (Housley, Nardelli et al. 2019). Through multiscale study of a class of 
sensory neurons in animals with cancer treated by chemotherapy, we discovered the 
first evidence that CIN cannot be explained by the effects of chemotherapy alone but 
depend instead on complex interactions with cancer-related processes. Among the 
observed changes across genetic, protein and whole cell neurologic function, neurons 
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failed to encode natural movement stimuli in their spiking activity with dysfunction 
depending on both cancer and chemotherapy. 
A key question that remains relates to whether the cancer—chemotherapy 
codependence that causes dysfunction in neuronal encoding is conserved across 
diverse classes of mechanosensory neurons. Mechanosensory neurons are necessary 
for generating the information content (population code) needed for proprioception. For 
example, Golgi tendon organs (Ib) and group Ia and II muscle spindle afferents encode 
unique static and time-varying information, e.g. length, velocity, and inertial loads of 
body position as movements result in physical interactions with the environment. If 
deficits are conserved across the population, conflicting sensory signals or deletions of 
critical pieces of information would prove detrimental for a unified representation of body 
position under static and dynamic conditions, e.g. proprioception.  Deficits in this 
population code may explain the lasting perceptual and functional deficits documented in 
patients treated with chemotherapy. Alternatively, the central nervous system (CNS) 
may compensate for the loss of information by learning a new representation of the 
population code to partially or fully compensate for information loss, thus preserving 
proprioception performance. Therefore, developing a detailed understanding of 
dysfunction across the population is necessary for developing mechanistic 
understanding, for predicting functional deficits or for understanding how the CNS may 
compensate for profound information loss.  
The present study was designed to test the hypothesis that cancer’s 
exacerbation of chemotherapy induced neuronal signaling deficits is conserved across 
the population of mechanosensory neurons in muscle. We recorded intracellular spiking 
activity from four classes of physiologically identified mechanosensory neurons 
responding to naturalistic mechanical stimuli in vivo. Results support our hypothesis in 
finding significant deficits in spike encoding across multiple measures used to 
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parameterize responses to naturalistic stimuli in all neuron classes. Analyses reveal co-
suppression of specific signaling parameters across all neuronal classes, suggesting the 
existence of a global co-regulatory process that governs the balance of information 
content from multiples neuron classes flowing to the central nervous system. To 
understand the consequences of corrupt population spiking activity, we employed deep-
learning algorithms to test how decoding of spatiotemporal features of movement are 
altered after chemotherapy treatment of cancer. Results indicate that spiking activity 
from the population of neurons in animals with cancer, treated by chemotherapy contain 
significantly less information about key features of movement including: timing, 
magnitudes, and velocity. We then modeled the CNS’s capacity to compensate for this 
information loss by retraining the networks on corrupt population codes which revealed 
the CNS would not be able to fully compensate (learn) a new representation that 
restores predictive abilities. Intracellular recordings of synaptic potentials in a CNS 
neuron provided biological validation of modeling results confirming upstream neurons 
ability to accurately predict stimuli remain impaired. Collectively, our results show global 
deficiency in the population code of mechanosensory neuron population and resulting 
corrupt spatiotemporal decoding of movement features necessarily results in upstream 
neurons or networks to unpredictable inferences about the bodies interaction with the 
external environment and may contribute to lasting behavioral deficits documented in 
patients treated with chemotherapy.  
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Aim 6: Test the hypothesis that cancer’s exacerbation of 
chemotherapy induced neuronal signaling deficits is conserved 
across the population of mechanosensory neurons in muscle. 
Aim Specific Methods 
Neuronal Classification 
Dorsal rootlets positioned in continuity on bipolar recording electrodes were selected for 
sampling sensory neurons when they produced robust population activity (extracellular 
responses from many sensory neurons) in response to both electrical stimulation of 
triceps surae nerves and stretch of triceps surae muscles. Individual axons penetrated in 
these rootlets by glass micropipettes (~30 MΩ filled with 2 M K+ acetate) were selected 
for study when electrical stimulation of triceps surae nerves produced orthodromic action 
potentials that were readily resolvable and had conduction delay of <3 ms. We classified 
muscle afferents on the basis of their responses to specific stimuli, e.g., muscle twitch 
contraction and vibration on  basis of binary scoring of three criteria (Vincent, Gabriel et 
al. 2017). Afferents that fired during the rising phase of isometric twitch force (evoked by 
nerve stimulation with electrical pulses 0.04-ms duration at 1 pps) were designated 
group Ib tendon organ afferents, while those that did not were labeled muscle spindle 
afferents. Muscle spindle afferents designated Ia were distinguished from group II by 
firing with virtually perfect entrainment to 1-s bouts of high-frequency, small-amplitude 
vibration (100 –333 Hz, 80 µm) and by responding with an initial burst of high-frequency 
firing (>100 pulses per second (pps)) at the onset of muscle stretch. These same criteria 
distinguish analogous afferent groups in the cat (Matthews 1972). 
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Population code construction 
Intracellular recordings from physiologically identified sensory neurons of all four classes 
were used to construct population codes (ensembles of neuronal firing). Since identical 
natural stimulation patterns were used for all neuronal recordings, the stimulation profiles 
were used to precisely time synchronized independently recorded neurons. This allowed 
us to model population codes of physiologically identified neurons of precisely known 
locations from ApcWT+control and ApcPirc/++ OX animals, not possible in previous studies 
(Stein, Weber et al. 2004; Weber, Stein et al. 2007). 
Results 
Encoding deficits conserved across diverse classes of mechanosensory neurons 
Applying electrophysiological methods to rats in vivo, we recorded spiking activity from 
single mechanosensory neurons responding to naturalistic mechanical stimuli (Figure 
30). We sampled group Ia, unclassified spindle, group Ib, and group II totaling 225 
neurons from ApcWT+control, ApcWT+OX, ApcPirc/++control, and ApcPirc/++OX experimental 
groups (Figure 30 and see Table 2 for complete description). For simplicity raw data and 
canonical analyses of group Ia neurons are not reproduced from Project 1.  
Table 2.  
Distribution of decoding data. Breakdown of data from 225 neurons acquired from 20 animals. Neuronal 









ApcWT+control (n=6) 11 19 17 14 
ApcWT+OX (n=3) 19 14 9 5 
ApcPirc/++control (n=4) 20 19 17 18 





From these spiking responses, we collected 31 measured and derived parameters 
(average of four trials: (Figure 20 and Table 3).  In ApcWT+control rats, we found that 
muscle stretch elicited the expected spike encoding behavior from multiple classes of 
sensory neurons in normal animals (Vincent, Gabriel et al. 2017) and humans (Burke, 
Hagbarth et al. 1978) (grey traces Figure 30).  We next asked whether ApcPirc/+ or OX 
treatment alone induce signaling dysfunction. In agreement analyses of group Ia 
neurons presented in Aim 3, we found a remarkable degree of concordance with 
signaling in ApcWT+control (Figure 30). ApcPirc/++control neuronal signaling displayed 
comparable sensitivity to stimuli and showed similar static behavior across all neuronal 
classes (red traces in Figure 30) as the ApcWT+control with the exception of group II 
neurons that spiked longer ApcWT+control. As was true for group Ia neurons, OX 
treatment of ApcWT rats induced mild signaling deficits. Deficits were primarily restricted 
to sustained firing (blue traces in Figure 30), validating our previous findings of restricted 
deficits observed in a different strain of healthy rats treated with OX alone (Vincent, 
Wieczerzak et al. 2016). 
Table 3.  
Summary Statistics of Neuronal Signaling. Breakdown of summary statistics of each neuronal class and 
their respective signaling parameters.   
Group II ApcWT+control N=17 ApcWT+OX N=9 ApcPirc/++control N=17 ApcPirc/++OX N=14 
Variables Mean SEM Mean SEM Mean SEM Mean SEM 
Dyn.DI 61.28 4.68 48.33 5.74 60.96 8.22 38.34 5.73 
Dyn.F 156.71 18.43 172.44 25.23 188.05 25.04 186.48 16.02 
Dyn.IFRdrop 29.61 6.3 18.86 4.35 30.88 8.7 51.41 19.87 
Dyn.pfr 127.93 5.35 103.8 15.02 118.42 11.73 72.08 9.81 
Dyn.pfr1 102.29 8.13 89.95 17.29 94.2 8.75 64.59 6.45 




Table 3 continued 
Dyn.RDR 17.47 1.7 12.33 2.39 12.76 1.44 5.79 1.71 
Dyn.slp 700.22 71.12 628.37 62.21 1114.62 154.25 777.86 140.92 
Dyn.slp1 87.3 8.96 111.97 18.06 131.08 14.4 139.41 27.93 
Dyn.slp3 147.04 18.81 138.17 21.61 181.14 22.34 135.78 27.54 
Dyn.spkNum 11.54 0.54 10.19 1.31 8.65 0.88 5.23 0.74 
Dyn.spkNum1 48.18 4.07 38.11 8.31 37.06 3.93 17.43 3.05 
Dyn.spkNum3 30.94 3 25.78 6.26 24.29 2.78 11.64 1.73 
Stat.afr 73.19 4.76 64.44 10.39 66.15 6.37 38.54 5.7 
Stat.HzEnd 56.87 5.22 52.77 8.73 50.02 5.45 23.44 5.45 
Stat.HzSTD 19.03 1.37 26.19 9.28 21.35 3.42 14.78 2.07 
Stat.LSpkF 110.75 9.87 107.43 4.92 112.21 10.11 105.39 4.79 
Stat.LSpkT 994.73 1.18 964.82 27.9 991.11 2.05 906.6 68.3 
Stat.mSfr 66.65 4.84 55.91 10.3 57.46 5.71 32.91 5.59 
Stat.slp -44.31 2.51 -38.18 5.19 -45.92 5.5 -31.41 3.66 
Stat.spkNum 67.99 5 57.82 10.33 59.56 6.52 33.39 5.63 
Thr.F 11.03 0.84 13.64 1.1 22.9 4.01 31.6 8.04 
Thr.F1 8.15 1.37 24.85 8.71 20.84 4.33 41.64 10.85 
Thr.F3 17.65 2.99 35.48 10.46 31.58 5.28 47.45 10 
Thr.L 0.16 0.03 0.2 0.03 0.55 0.11 0.89 0.22 
Thr.L1 0.18 0.06 0.57 0.23 0.55 0.14 1.08 0.22 
Thr.L3 0.76 0.1 1.07 0.24 1.16 0.12 1.44 0.15 
Thr.T 8.84 1.35 9.52 1.63 26.77 5.36 45.32 10.69 
Thr.T1 43.64 14.28 145.93 58.69 136.98 33.67 267.06 55.02 











Table 3 continued 
Group Ib ApcWT+control N=14 ApcWT+OX N=5 ApcPirc/++control N=18 ApcPirc/++OX N=14 
variable Mean SEM Mean SEM Mean SEM Mean SEM 
Dyn.DI 68.41 7.14 72.24 6.36 41.95 5.34 26.99 8.49 
Dyn.F 286.55 13.76 214.62 35.18 226.12 24.98 265.07 24.01 
Dyn.IFRdrop 23.91 4.38 35.98 15.08 22.46 5.68 60 16.89 
Dyn.pfr 145.78 13.51 102.36 4.3 95.11 8.41 40.78 11.74 
Dyn.pfr1 149.61 11.69 98.32 7.22 101.84 11.1 53.72 9.36 
Dyn.pfr3 136.6 11.08 92.55 6.99 93.02 10.82 41.59 9.97 
Dyn.RDR 7.64 0.89 8.2 3.34 10.94 1.22 2.5 0.57 
Dyn.slp 2144.72 323.56 1708.74 735.8 1146.52 260.42 336.44 137.58 
Dyn.slp1 259.76 54.67 297.86 91.14 160.45 22.37 267.74 61.51 
Dyn.slp3 377.86 31.98 381.65 81.26 189.87 32.28 202.51 49.17 
Dyn.spkNum 7.98 0.84 7 1.7 6.35 0.68 2 0.46 
Dyn.spkNum1 33.93 4.02 23.4 5.21 32.39 3.62 7.21 1.86 
Dyn.spkNum3 26.29 3.66 15.2 2.63 21.44 2.94 4.79 1.38 
Stat.afr 87.79 8.26 58.71 3.88 57.98 4.52 42.3 8.81 
Stat.HzEnd 62.88 9.55 6.56 6.34 44.42 4.72 9.96 5.56 
Stat.HzSTD 26.67 2.44 20.11 2.15 14.29 1.32 14.28 3.7 
Stat.LSpkF 166.04 15.23 121.93 16.86 121.61 13.73 149.08 11.96 
Stat.LSpkT 990.38 4.08 752.28 63.25 990.31 2.55 316.84 113.42 
Stat.mSfr 75.54 8.42 39.67 4.67 52.33 4.27 13.06 6.54 
Stat.slp -61.81 5.23 -90.77 16.72 -36.71 3.25 -51.03 24.47 
Stat.spkNum 79.95 8.56 28.75 5.14 53.57 4.44 14.13 6.7 
Thr.F 47.86 10.39 47.16 22.01 37.04 10.22 96.39 19.51 
Thr.F1 66.42 9.93 82.25 30.21 37.61 10.41 121.7 20.69 
Thr.F3 83.46 9.32 102.23 26.18 55.65 10.5 126.48 24.76 
Thr.L 1.01 0.18 0.86 0.44 0.78 0.17 1.86 0.28 
Thr.L1 1.37 0.17 1.42 0.47 0.77 0.17 2.2 0.2 
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Table 3 continued 
 
Thr.L3 1.78 0.1 1.99 0.25 1.55 0.12 2.13 0.26 
Thr.T 50.71 9.18 53.76 24.54 37.47 8.4 96.96 14.29 
Thr.T1 324.18 49.42 360.65 119.97 177.2 42.28 562.46 35.74 





ApcWT+control N=19 ApcWT+OX N=14 ApcPirc/++control N=19 ApcPirc/++OX N=5 
variable Mean SEM Mean SEM Mean SEM Mean SEM 
Dyn.DI 106.72 7.95 120.52 11.13 129.67 7.12 84.38 13.96 
Dyn.F 248.81 21.74 159.98 12.59 233.98 24.84 143.33 11.79 
Dyn.IFRdrop 72.86 8.77 92.57 9.06 114.26 8.42 65.1 15.26 
Dyn.pfr 173.79 7.42 168.61 11.11 185.4 8.79 103.32 13.77 
Dyn.pfr1 131.93 4.55 112.07 8.44 134.35 8.23 73.43 13.06 
Dyn.pfr3 134.16 6.99 104.16 8.3 132.48 8.46 61.9 18.76 
Dyn.RDR 20.68 1.02 13.43 2.18 19.11 1.64 7 0.63 
Dyn.slp 1459.37 140.71 2001.68 220.49 1677.63 93.59 1641.3 358.14 
Dyn.slp1 142.08 7.59 168.86 10.62 175.21 11.23 189.73 33.6 
Dyn.slp3 213.73 12.52 246.02 19.92 274.11 19.28 225.45 69.6 
Dyn.spkNum 13.12 0.6 10.32 0.8 11.87 0.75 4.65 0.52 
Dyn.spkNum1 60.63 2.99 38.64 4.26 52.37 4.15 15.6 2.8 
Dyn.spkNum3 39.42 2.65 25.21 2.67 33.26 3.51 8.6 2.93 
Stat.afr 73.84 3.97 68.92 4.23 68.11 3.65 46.48 6.27 
Stat.HzEnd 49.15 5.95 40.71 5.13 44.91 3.78 12.3 7.56 
Stat.HzSTD 27.23 2.22 35.2 4.22 35.11 2 31.25 5.71 
Stat.LSpkF 116.26 8.71 109.91 7.57 121.45 9.06 110.13 9.71 
Stat.LSpkT 985.25 5.95 899.9 45.2 992.09 1.45 497.85 128.72 




Table 3 continued 
Stat.slp -58.45 5.52 -69.11 6.88 -71.93 4.44 -195.39 34.99 
Stat.spkNum 64.39 4.49 50.84 4.53 56.68 3.76 16.53 6.52 
Thr.F 17.59 1.59 31.18 3.61 22.34 3.57 41.44 10.09 
Thr.F1 11.96 2.24 29.91 4.19 15.81 2.13 49.01 6.85 
Thr.F3 31.06 2.7 46.32 6.19 39.18 3.97 78.01 18.59 
Thr.L 0.51 0.08 0.89 0.12 0.54 0.08 1.38 0.33 
Thr.L1 0.21 0.05 0.75 0.12 0.37 0.07 1.69 0.16 
Thr.L3 1.01 0.09 1.4 0.14 1.29 0.07 2.33 0.19 
Thr.T 25.02 3.87 45.12 6.23 25.56 4 112.06 50.34 
Thr.T1 53.35 14.85 214.73 41.31 91.38 16.68 419.77 39.16 





Group Ia ApcWT+control N=11 ApcWT+OX N=19 ApcPirc/++control N=20 ApcPirc/++OX N=10 
variable Mean SEM Mean SEM Mean SEM Mean SEM 
Dyn.DI 120.23 12.93 116.75 6.16 149.53 7.78 108.85 11.9 
Dyn.F 185.55 25.91 160.02 12.99 251.45 28.39 150.63 7.95 
Dyn.IB 282.63 14.33 205.66 36.76 175.31 48.52 76.12 51.18 
Dyn.IFRdrop 86.41 10.38 111.06 6.46 87.5 8.93 82.52 8.41 
Dyn.pfr 203.16 15.79 186.39 5.71 224.28 10.06 134.27 4.21 
Dyn.pfr1 150.52 11.87 137.87 5.8 172.9 14.55 107.62 7.79 
Dyn.pfr3 137.51 16.15 130.91 5.5 166.29 10.42 99.15 6.12 
Dyn.RDR 24.64 2.63 23.05 1.29 28 1.8 14.1 1.47 
Dyn.slp 929.94 137.19 1103.86 110.65 1243.56 104.05 1373.12 177.08 
Dyn.slp1 124.51 18.98 144.3 7.99 164.65 11.12 160.04 31.58 
Dyn.slp3 206.58 31.49 226.11 9.04 271.66 17.3 250.56 34.01 
Dyn.spkNum 18.77 1.41 16.04 0.82 17 1.27 9.9 0.9 
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Dyn.spkNum1 72.73 7.75 61.53 4.31 79 6.09 35.6 3.77 
Dyn.spkNum3 48.09 5.45 38.47 3.81 51 4.5 21.5 2.5 
Stat.afr 93.98 6.64 84.97 3.61 88.05 4.34 67.6 4.88 
Stat.HzEnd 73.47 6.47 50.72 7.09 62.75 4 24.02 8.41 
Stat.HzSTD 29.85 3.15 29.26 2.1 37.23 2.21 35.69 3.71 
Stat.LSpkF 122.5 11.3 113.24 10.12 115.67 8.63 120.71 7.15 
Stat.LSpkT 991.44 6.28 877.94 52.03 994.86 1.85 723.29 115.62 
Stat.mSfr 82.93 6.28 66.23 6.58 74.75 3.8 34.78 7.4 
Stat.slp -59.42 7.87 -153.24 73.55 -75.47 4.55 -289.61 145.17 
Stat.spkNum 85.64 6.57 66.88 6.27 76.8 4.25 36.8 7.36 
Thr.F 9.86 1.07 14.41 1.09 13.25 1.47 20.62 3.84 
Thr.F1 7.14 1.8 16.37 2.37 7.08 0.92 21.71 5.84 
Thr.F3 19.44 3.3 36.32 3.36 29.64 3.46 37.72 4.66 
Thr.L 0.09 0.01 0.24 0.03 0.2 0.05 0.65 0.16 
Thr.L1 0.15 0.07 0.4 0.09 0.07 0.01 0.72 0.2 
Thr.L3 0.84 0.12 1.31 0.09 0.91 0.08 1.48 0.11 
Thr.T 6.18 1.36 13.09 2.01 9.68 2.3 33.01 7.74 
Thr.T1 29.89 12.06 102.97 23.37 16.16 3.61 192.75 58.1 










Impaired Mechanosensory Neuron Population Code After Cancer Treatment. a-c. Representative 
cases of spiking activity in ApcWT+control (grey), ApcWT+OX (blue), ApcPirc/++control (red) and ApcPirc/++ OX 
(purple) as a measure of sensory encoding in unclassified spindle (a), group II (b), and group Ib (c). Black 
circles plot instantaneous firing rates (pps) of corresponding spike (action potential) intervals. Dashed 
vertical line marks onset of muscle stretch (3mm from resting length (Lo)) shown in bottom trace divided into 
dynamic and static phases by dark grey (150ms duration after stretch command onset) and light grey (1s 
duration after the dynamic phase) bars. d-f. Neuronal spiking parameters (n=31, averaged from four trials, 
from each neuron in each of the neuronal classes, unclassified spindle (d), group Ib (e), and group II (f). 
Features represent different features of sensory stimuli and were subjected to linear discriminant (LD) 
analysis. Neuronal signaling was visualized in the new 3D composite space created by LD1-3. 3D ellipsoids 
enclosing 68% of data were computed with least-squares elliptical fitting. Effects of independent (OX or 
ApcPirc/+) and combinatorial (ApcPirc/++OX) treatment are indicated by colored curved arrows. 
 
Purple traces in Figure 30 illustrate representative firing profiles for each neuron class in 
ApcPirc/++OX rats. We found drastically impaired neuronal signaling across all classes. 
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Sensitivity to stimuli was reduced at both high and low velocity stretch (data not shown). 
During dynamic stimuli, we found marked reduction in the number of spikes over both 
stretch conditions. Neurons also failed to sustain firing. In addition, we observed fewer 
spikes during rapid accommodation immediately preceding signal deletion, despite 
constant stimulus. These data confirm that a damaging functional interaction between 
the systemic effects of cancer and chemotherapy is conserved across multiple classes 
of sensory neurons in living animals.  
To quantify inferences drawn from raw data, we took an unbiased statistical approach by 
subjecting all signaling parameters from all neurons, classes and experimental groups to 
a LD analysis. This reduced complex feature space into canonical variables giving us a 
high-level understanding of where interaction emerges, without biased parameter 
selection a priori. Our analysis yielded three canonical variables (Figure 30d-f) that 
achieved overall 98.7% classification accuracy. We then visualized neuronal signaling in 
the new 3D composite space created by LD1-3 (Figure 30d-f) revealing a first dimension 
(LD1) that accounted for a large fraction of the explained variance for each class of 
neurons, ranging from 64-66% (Figure 30 d-f). Coincidentally, LD1 also represented the 
non-linear interaction between cancer and chemotherapy, that can be visualized by the 
3D separation of the purple spheroid in LD1 (as was the case for group Ia).   
By examining the discriminant function coefficients, we found that fast and slow 
threshold levels, static firing average (and number of spikes), and dynamic firing rates 
represent the dominant portion of the explained variance in LD1. This suggests that 
these parameters are most susceptible to codependent interaction and justify further 
quantification and validation. Line graphs in (Figure 31) show the hierarchal Bayesian 
modeling results for the selected parameters as well as the experimentally measured 
data used to power the generative models. Across all parameters and neurons classes 
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the codependent interaction significantly exacerbated signaling deficits.  Interestingly, 
the balance of parameter values between neuronal classes, e.g. the relative thresholds 
between group Ia and Ib, appear to be conserved, which suggest a global co-regulatory 
process may be present. In other words, a process that governs the balance of 
information content from multiples neuron classes flowing to the central nervous system. 
Collectively, our data indicate that all muscle proprioceptors are vulnerable to neurotoxic 








Co-Suppression of Key Mechanosensory Features. Hierarchal Bayesian modeling results used to test for 
significant group differences of neuronal spiking parameters (six shown). Colored and shape coded points 
represented the empirically derived mean posterior predictive density and 95% highest density intervals 
(vertical lines). Statistically significance is determined when vertical lines do not overlap between 
parameters, i.e. 95% highest density intervals are exclusive. Insets in each model output display boxplots of 
experimentally measured data used in hierarchal models. 
Latent Mechanosensory Features Similarly Impaired 
We leveraged an unsupervised analytical approach, principal component analysis 
(PCA), to validate the supervised analyses performed above. PCA was simultaneously 
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applied to 31 parameters of mechanosensory encoding measured in response to natural 
stimuli for all classes and experimental groups. PCA confirmed fast and slow threshold 
levels, static firing average and number of spikes, and dynamic firing rates represent the 
parameters most indicative of groupwise separation (vectors in (Figure 32a). Neurons 
were then visualized in the new latent feature space created by PC1–3 where individual 
points represent individual neurons. Failure to adequately separate groups by either 
class (Figure 32b, unclassified spindle: green, group Ib: blue, group II: purple, and group 
Ia: yellow) or treatment group (Figure 32c, ApcWT+control: grey, ApcWT+OX: blue, 
ApcPirc/++control: red and ApcPirc/++ OX: purple) indicates substantial class by treatment 
interaction. To overcome this, neurons were co-labeled based on class and treatment. 
Mean centroids were calculated and visualized in 2D projections (Figure 32d and 
expanded view of dotted box in Figure 32d) created from PC1-2. Vectors were 
calculated to show the magnitude and direction of independent (OX or ApcPirc/+) and 
combinatorial (ApcPirc/++OX) treatment effects across each class in the latent feature 
space. ApcPirc/+ consistently influenced PC2, whereas OX effects consistently acted on 
PC1. While ApcPirc/++OX similarly acted on PC1, the magnitude was significantly greater 
than that observed from OX. Interestingly, linear summation of OX and ApcPirc/+ effects 
does not accurately predict the location of ApcPirc/++OX. Collectively, our results confirm 
that using cancer or chemotherapy as independent predictor fails to accurately predict 
their combination. Further, our analyses indicate that despite unique encoding properties 
and firing profiles, the combinatorial effects of cancer and chemotherapy influence 
neuronal firing in a similar manner. This becomes evident when high dimensional 
parameter spaces, that accurately described neuronal firing, are simplified to low-





Latent Mechanosensory Features Similarly Impaired Across Diverse Mechanosensory Neuron 
Classes. Principal component (PC) analysis was applied to 31 parameters of mechanosensory encoding 
measured in response to natural stimuli. a, vectors represent the magnitude and direction of correlation 
between individual parameters and the two latent features capturing the most variance (PC1-2). b-c, 
Neurons visualized in the new latent feature space created by PC1–3. Points represent individual neurons 
highlighted by specific mechanosensory class (b, unclassified spindle: green, group Ib: blue, group II: purple, 
and group Ia: yellow) or treatment group (c, ApcWT+control: grey, ApcWT+OX: blue, ApcPirc/++control: red and 
ApcPirc/++ OX: purple). Neurons were co-labeled based on class and treatment and mean centroids were 
calculated and visualized in the 2D projections (d) created from PC1-2. e, expanded view of dotted box in d. 
Magnitude and direction of arrows demonstrates the independent (OX or ApcPirc/+) and combinatorial 
(ApcPirc/++OX) treatment effects across the latent feature space.  
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Population level deficits do not reflect hypoexcitable scaling 
Having established codependent interactions are conserved across multiple sensory 
neuron classes, we aimed to understand the consequences of those deficits when the 
information is convolved in a population code as it is at a sensorium level. Intracellular 
recordings from physiologically identified sensory neurons of all four classes were used 
to construct population codes (ensembles of neuronal firing). We precisely time 
synchronized independently recorded neurons by aligning identical stimulation patterns. 
This allowed us to model population codes of physiologically identified neurons of 
precisely known locations from ApcWT+control and ApcPirc/++ OX animals, not possible in 
previous studies (Stein, Weber et al. 2004; Weber, Stein et al. 2007).  Figure 33 
presents the population code of 40 neurons recorded each from both ApcWT+control rats 
(grey) and ApcPirc/++ OX rats (purple). Visual inspection of the ApcWT+control population 
reveals that while variable firing responses exist (top panel), likely reflecting the diverse 
encoding properties of multiple neuron classes, the average firing rate (bottom panel) 
closely mirrored the stimuli (bottom traces), both in onset and shape. By contrast, the 
sparse ApcPirc/++ OX population (top panel) displayed delayed onset and reduced 






Blunted Population Code. Population code of 40 neurons recorded each from both ApcWT+control rats 
(grey) and ApcPirc/++ OX rats (purple). Vertical lines in raster plot (top panel) indicate the presence of 
individual spiking events during a representative 10s recording as three slow (4mm/s) ramp-release followed 
by three, fast (20mm/s) ramp-hold-release mechanical stimuli initiate neuronal activity. Bottom panel 
illustrates the average firing rate (black line) and standard error (shaded region) computed from the same 
recording epoch as above. Both population codes were constructed from the same distribution of neuronal 
classes, 10 group Ia, 5 unclassified spindle, 14 group Ib, and 11 group II. 
 
Summary 
Collectively, results confirm the expected blunted population code while also providing 
the first evidence that the codependent interactions does not result in a simple 
hypoexcitable scaling, as evidence by substantial temporal dispersion.  
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Aim 7: Test the hypothesis that decoding of spatiotemporal 
features of movement from a population code of 
mechanosensory neurons is attenuated after chemotherapy 
treatment of cancer. 
Aim Specific Methods 
General deep learning methods 
We leverage deep, recurrent artificial neural networks to discover structure in high 
dimensional inputs (binned ensemble neuronal firing rates). These methods are inspired 
by biologically plausible models of neural circuits, particularly the spinal sensory-motor 
circuits studied here, that learn a hierarchical representation or transformation of the 
input data that make prediction easier (Rumelhart, Hinton et al. 1988; Goodfellow, 
Bengio et al. 2016). The deep neural network utilized here, consists of a layer of 
computational units called neurons or nodes. The deepness refers to the number of 
layers between the input and output. We selected a single hidden layer that represents 
the LV/VI interneuronal populations that is fully connected to the output layer. 
Biologically these interneuronal populations receive a vast synaptic connections from the 
mechanosensory neurons (input data) studied here (Vincent, Gabriel et al. 2017) and 
reside directly upstream of the motor pools (analogous to our output layer). By tuning the 
connection weights, the network can learn to approximate a function used for prediction, 
i.e. how a motor pool receiving this synaptic input could draw inferences about its 
previous activity. In this work we are interested in training a deep neural network to 
decode (extract) relevant musculoskeletal features of the rat hindlimb from activity 
recorded from ensembles of healthy mechanosensory neurons activity and how that 
ensemble of neuronal activity is altered following cancer treatment (Figure 33). This 
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approach allows predictions to be made of specific sensory-motor deficits not possible 
from analyzing spike trains alone. Because both the full structural and functional 
connectivity remain unknown throughout the segmental spinal circuits we chose a fully 
connected schema throughout as a rational starting point. 
Model architecture. 
The model architecture was constructed using the Keras library for Python (Chollet 
2018), using TensorFlow backend (Abadi, Agarwal et al. 2016). The architecture relates 
the multidimensional input (binned neuronal firing rates) to output (musculoskeletal 
parameter) space, as described in Figure 34. The model considered not only the current 
time bin but the six-time bins that preceded and followed it to better inform its decisions 
about the musculoskeletal parameters. The network comprised a single layer of long-
short-term memory units (LSTMs), a modification on the basic recurrent structure that 
minimized the impact of numerical instability during back-propagation and further 
improve the capture of long-term dependencies (Hochreiter and Schmidhuber 1997). 
The LSTM units were fully connected to an output layer with three units (length, force, 
stiffness) using RMSprop (Tieleman and Hinton 2012) as the optimization routine. 
Models were run with GPU parallelization using NVIDIA’s cuDNN package (v 7.6). To 
combat the tendency to overfit unconstrained predictors, particularly on smaller data 
sets, we utilized an effective method to curb overfitting. We used a technique called 
dropout to prevent complex co-adaptations, or paired relationships between units in the 
network by allowing connections between individual units to be removed with some 
specified probability, range from 0-1, during training (Srivastava, Hinton et al. 2014; Gal 
and Ghahramani 2016). The specific dropout probability was set as a hyperparameter 
prior to training during each fold. This and other hyperparameters, e.g number LSTM 




Input data (neuronal activity) was z-score normalized. Output data (musculoskeletal 
parameter) was zero-centered. Data for training/validation/testing were preprocessed 
using identical approaches.  
Predictive Performance  
Predictive performance of models was measured as the fraction of variance accounted 




) where 𝑦N/  are the predicted values, 𝑦/ are the true values, 
and 𝑦P/ is the mean value. R2 values are reported for each musculoskeletal parameter: 
length, force, and stiffness.  R2 values in the range [0, 1] are interpreted in the same 
way as the Coefficient of Determination. Negative R2 values are interpreted as the 




Conceptual schematic of encoding and decoding processes.  Encoding is the process by which static 
and dynamic musculoskeletal parameters (top right) is translated into ensembles of spiking neurons. 
Decoding is the process by which information, e.g. about the musculoskeletal parameters, is extracted from 
spiking activity. Bottom inset illustrates the decoding methodology via artificial neural network. To decode 
(predict or extract information from spikes) the output in a given time bin, the firing rates of all neurons 
(N=40) in time bins (bins=3), In this schematic, one bin preceding the output, one concurrent bin, and one 
following bin). Here, we show two outputs being predicted for simplicity but we report three outputs; muscle 




Models were assessed using a 10-fold cross-validation approach by splitting the data 
into a training, validation and testing sets (Stone 1974; Browne 2000). For each fold, a 
separate model was constructed, leaving that fold out for use as test data and using 
eight of the remaining folds as training data. The test data fold was used to compare the 
performance across different model forms. The one remaining fold was used as a 
validation data set: model performance with respect to this data set was used to select 
some independently optimize hyperparameters (described below) before evaluating the 
model for comparison with other model forms using the test data thereby eliminating any 
bias introduced by selecting hyperparameters on the basis of the test performance 
(Bishop 1996). For each fold, models were trained to minimize the mean squared error 
between the predicted and true musculoskeletal parameter of the training data.  
Hyperparameter optimization  
In addition to parameters that link the neural activity to the output variables, e.g. weights 
on connections in network, the model also has hyperparameters, which relate to the 
design of the network itself that needs to be identified prior to training. Unbiased 
hyperparameters (number of hidden units in the layers, amount of dropout (Srivastava, 
Hinton et al. 2014), and number of training epochs) selection was performed on each 
cross-validation fold. Optimization was directed to identify hyperparameters that led to 
the highest R2 on the validation set using Bayesian optimization (hyperopt Python 
package) (Bergstra, Yamins et al. 2013). This algorithm uses a Bayesian-based 
optimization algorithm called the Tree-structured Parzen Estimator to explore a 
hyperparameter space across multiple epochs. Briefly, this optimization approach 
samples hyperparameter values from pre-defined prior distributions, uses a loss function 
to evaluate the current hyperparameters, and then repeats these steps using knowledge 
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gained from the evaluations it has already performed. After a desired number of epochs, 
the hyperparameter set associated with the minimal loss value across all epochs is 
chosen as the optimal hyperparameter set. Those hyperparameters were used to 
calculate the R2 value on the testing set.  
In Vivo Validation of Decoding Deficits  
Biological validation of decoding results was obtained by recording synaptic potentials in 
triceps surae motoneurons in response mechanical stretch of the triceps surae muscles. 
The triceps surae muscles were stretched by 3mm at a constant velocity (20 mm/s) over 
150ms rise during ramp-hold-release stretch, the muscles were held at that length for 1s, 
and then released to resting length at constant velocity over 150ms. Stretches were 
repeated for 15-20 trials at 4-s intervals then averaged. 
Results 
High fidelity feature extraction by healthy nervous system 
Since the ApcPirc/++ OX population code was not a downscaled ApcWT+control 
sensorium, the potential for information loss encouraged us to test the consequences of 
the ApcPirc/++ OX population. We employed a deep-learning algorithm (long-short-term 
memory network: LSTM) to test how decoding of spatiotemporal features of movement 
are altered after chemotherapy treatment of cancer. The process of decoding allows 
neurons and networks of neurons upstream of the sensorium to extract features of the 
spiking activity in order to draw inferences on that information, e.g. current body position 
or inertial loads on limbs as movements result in physical interactions with the 
environment. First, we aimed to understand LSTM performance when decoding the 
ApcWT+control sensorium. Figure 35 (left) summarizes average decoding performance 
quantified across all 10-fold cross validation runs for LSTM trained on ApcWT++control 
data. Results indicate highly accurate decoding of all parameters but muscle force was 
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consistently decoded more significantly more accurate than length or stiffness. Figure 35 
(right) shows representative raw traces of three ground truths and three model 
predictions generated after training.   
Figure 35. 
High fidelity feature extraction by healthy nervous system. a, Average decoding performance across all 
10-fold cross validation runs for model trained on ApcWT++control data. Boxes represent the three outputs 
(mechanical stimuli) being predicted by model force, length, stiffness. b, Raw traces of three ground truths 
(black lines) and three model predictions generated after training (color coded after a). Model contained 
~7.5x105 parameters. * indicates statistically significant differences as empirically derived from hierarchical 
Bayesian model (stan_glm): 95% highest density intervals do not overlap.  
Cancer treatment degrades accurate decoding 
We then computed the LSTM model performance when tested on the ApcPirc/++ OX 
population. Figure 36 illustrates the three musculoskeletal parameters with 
superimposed LSTM predictions for two types of stimuli, fast ramp-hold-release (a) and 
slow ramp-release (b). Figure 36c summarizes average decoding performance 
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quantified across all 10-fold cross validation runs when compared to ApcWT+control 
model performance. Significant degradation in predictive accuracy was observed with 
muscle force experiencing the greatest reduction in accuracy (R2=-0.03%) while length 
and stiffness conserved the greatest accuracy (R2 =20% and 30.2%).  
Figure 36. 
Cancer treatment degrades accurate decoding. a-b, Long-short-term memory (LSTM) model predictions 
of mechanical stimuli for ApcPirc/++ OX neuronal population (Purple) and ground truth (Black) for each of the 
three outputs. Model trained on ApcWT+control data and tested on same number and proportion (classes) of 
ApcPirc/++ OX neurons for various stimuli, e.g. fast ramp- hold-release (a) and slow velocity ramp-release 
stretches (b). b. Average decoding performance across all 10-fold cross validation runs for ApcPirc/++ OX 
neurons when compared to ApcWT+control performance. * indicates statistically significant differences as 





We then focused on specific features of the LSTM predictions to gain insight into where 
functional consequences may manifest during animal (human included) movement. 
Analyses quantified the features as defined in Figure 37a. We find significant errors were 
made for the background force and stiffness whereas background lengths were largely 
conserved (Figure 37b), significant lag in discriminating the onset of stimuli (Figure 37c), 
significantly impaired detection of sustained lengths, forces, and stiffnesses, as well as 
inconsistent predictions of peak forces and length changes.  
Figure 37. 
Functional consequences. a. Analytic schematic for measuring functional errors. b-f. Average errors for 
various parameters across the three outputs (length, force, stiffness) predicted by both ApcWT+control and 
ApcPirc/++ OX neuronal models. Boxes indicate average errors from ground truth, e.g. 0 is perfect prediction. 
* indicates statistically significant differences as empirically derived from hierarchical Bayesian model 
(stan_glm): 95% highest density intervals do not overlap. 
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Aim 8: Test the hypothesis that learning can compensate for a 
corrupt population code after chemotherapy treatment of 
cancer. 
Aim Specific Methods 
Reparametrizing Decoding Model 
To model how the CNS may compensate for a corrupt sensory population, restore 
predictive power and improve the accuracy of feature extraction, we trained a LSTM 
network, de novo, on the ApcPirc/++OX population hereafter designated LSTMOX. During 
training, this affords the LSTMOX access to ground truth. This affords iterative updating of 
the relationship between input data and predictive outputs and is a biologically plausible 
process by which the representations and transformations of neuronal input could 
update a unified representation of body position under static and dynamic conditions, 
e.g. learning or compensating. The LSTMOX was trained, tested and validated, under 
identical conditions as described above for the LSTM.  
 
Results 
CNS cannot fully compensate  
Figure 38 illustrates the three musculoskeletal parameters with superimposed LSTMOX 
predictions. LSTMOX performance was substantially improved as compared to the 
predictions (Figure 36a, b), yet fell significantly short of ApcWT+control model 
performance (Figure 35). This suggested that the CNS would not be able to fully 
compensate for and learn a new representation of the corrupt population code that 





CNS cannot fully compensate. Long-short-term memory (LSTMox) model predictions of mechanical stimuli 
for ApcPirc/++ OX neuronal population (purple) and ground truth (black) for each of the three outputs. Model 
trained, tested and validated ApcPirc/++ OX data for various stimuli, e.g. fast ramp- hold-release (right) and 
slow velocity ramp-release stretches (left). 
 
Project 2: Discussion  
Here we present original evidence that encoding deficits induced by chemotherapy, 
exacerbated by cancer are conserved across diverse classes of mechanosensory 
neurons. Our results show global deficiency in the population code of mechanosensory 
neuron population and resulting corrupt spatiotemporal decoding of movement features. 
Since these neurons are responsible for encoding the foundational spiking activity to 
generate a unified representation of body position under static and dynamic conditions, 
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their impairment necessarily results in upstream neurons or networks to unpredictable 
inferences about the bodies interaction with the external environment. By modeling the 
compensatory or learning processes, our results further suggest that the CNS would not 
have the capacity to fully compensated through learning. This inability may help to 
explain the lasting behavioral deficits documented in patients treated with chemotherapy.  
Redundancy as a Compensatory Mechanism 
Multiple classes of mechanosensory neurons combine their signals in a population code 
that is decoded by the CNS to regulate and perceive body movements and postures.   A 
large portion of that population code is uniquely provided by the neurons studied here, 
namely Golgi tendon organs (Ib) and group Ia and II muscle spindle afferents. 
Mechanosensory neurons are classically understood to encode unique time varying 
features of muscle mechanics. Dynamic muscle parameters are thought to be 
represented by group Ia afferents, static muscle parameters by group II afferents, and 
higher stretch threshold by group Ib afferents. Despite these unique capabilities, we 
have previously documented that this diverse population of neurons encode parameters 
that are distributed in a continuum with substantial overlap, e.g. robust Ib response to 
passive muscle stretch in the physiological range (Vincent, Gabriel et al. 2017). From 
this, we infer that the mechanosensory population code, is to some degree, redundant. 
While other have suggested that redundant codes may be unnecessary to decode 
information about movement (Stein, Weber et al. 2004), redundancy reduction can be 
problematic since codes maybe sensitive to noise and require careful processing when 
attempting to encoded and extract information (Schneidman, Bialek et al. 2003).  In fact, 
the existence of redundancy may actually indicate the prevalence of a stimulus, a critical 
factor in developing representation and performing analysis via probabilistic 
computations (Barlow 2001). Outside of probabilistic encoding or decoding processes, 
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specific behavioral success has been attributed to sensory feedback that emerges from 
both distinct and redundant mechanosensory sources (Akay, Tourtellotte et al. 2014). 
Sensory feedback from muscle spindles appears to selectively influence the pattern of 
flexor muscles activations during locomotion, whereas the joint responses of muscle 
spindles and Ib afferents determine the pattern of extensor muscle firing (Akay, 
Tourtellotte et al. 2014). Taken together, redundant mechanosensory population code 
may protect or compensate for losses in specific classes of neurons or encoded 
parameters in ApcPirc/++ OX rats or cancer survivors that have undergone chemotherapy 
treatment. Alternatively, dysfunctional encoding might overwhelm redundancies resulting 
in decompensated sensorimotor performance. Dysfunction might similarly arise during 
certain behaviors or phases of movement that depend on selective mechanosensory 
information. Population statistics, canonical analyses, and computational modeling 
provided rigorous tests of these hypotheses. In all cases, we find that the redundancy in 
the mechanosensory population code is insufficient to compensate for distributed 
information loss across each neuron class.  This finding strengthens the evidential 
support that mechanosensory deficits play a prominent role in behavioral deficits 
observed in clinical cancer settings.  These findings may also explain why ApcPirc/++ OX 
rat task performance is worse than our previous observations in animals treated with OX 
alone, in that selective dysfunction of muscle spindles static responsiveness was 
compensated, by redundant signals from Ib and II neurons.   
Clinical and Functional Significance 
While we have yet to establish a causal relationship, impaired sensory feedback has real 
potential to contribute to decompensated sensorimotor performance observed in our 
precision behavioral tasks in awake behaving animals (Aim 5) and is likely involved in 
instability and ataxia’s seen in cancer survivors (Burakgazi, Messersmith et al. 2011; 
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Tofthagen, Overcash et al. 2012; Kneis, Wehrle et al. 2016; Marshall, Zipp et al. 2017; 
Taleb, Bouzobra et al. 2017). This is due to the fact that these neurons provide the CNS 
with its only means of detecting mechanical perturbation in the muscular system. 
As we have previously documented, reasonable predictions about the consequences of 
corrupt signaling can be drawn from evaluating spike trains (neuronal signaling). 
However, the extent to which you can draw direct comparisons between neuronal 
signaling and their behavioral consequences is less certain given the precise nature and 
features of the transformation from external stimuli to action potentials remains 
unknown. This makes understanding objective consequences and making real-world 
predictions of compromised neuronal signals challenging.  
We took the first steps to overcome this limitation by using a deep-learning neuronal 
decoding algorithm in a novel way. Neural decoding typically uses population level data 
recorded from the nervous system to make predictions about variables in the outside 
world, e.g. arm position, that can be used to control devices (e.g., robotic limbs). In this 
way, neuronal decoding algorithms model the processes by which information is 
extracted by the CNS. We extended this analytic method to understand and quantify 
prediction errors that could be made when exposed to compromised neuronal signals. 
This allowed us to, for the first time, make quantifiable measures about what movement 
limitations would emerge from neuronal signaling deficit. Our analyses revealed several 
unexpected predictions including: both over and underestimation of applied forces, 
severe delays in detection of applied perturbation (in some cases adding 100s of 
milliseconds of delay, e.g. Figure 38), and drift in perceived length changes despite 
constant stimuli. These unique insights should inform the focus of future clinical 





The CNS has a vast capacity to reorganize or develop a new representation following 
insult (Chen, Cohen et al. 2002; Anderson, Spencer-Smith et al. 2011; Ionta, Villiger et 
al. 2016). To investigate this role, we also took the first steps toward understanding the 
CNS’s capacity to compensate for signaling loses by modeling the maximum decoding 
potential when our deep-learning neural decoding was given access to ground truth 
during optimization. This advantage improved the accuracy of decoding external states 
yet revealed that substantial errors persist. Moreover, these data further support our 
hypothesis that sensory encoding deficits contribute to functional limitations and that 
despite the impressive capacity for reorganization, the CNS would not be able to fully 
compensate.  
It remains to be seen how deficits in primary afferent signaling propagate to higher 
network level dysfunction, e.g. perception, body schema despite is suspected dominant 
role in on-line representations (Shenton, Schwoebel et al. 2004). Our modeling was 
limited by the fact that we estimated errors that the CNS may make if it were only 
exposed to mechanosensory neuron populations. In this way, our modeling approximate 
spinal neurons populations, e.g. motoneurons, pre-motoneurons, dorsal spinocerebellar 
tract (DSCT) neurons, etc. best. These neuron populations have limited access to other 
forms of sensory information that may augment losses. While no compensation can be 
made for absent/corrupt primary afferent information, its precise contribution to errors in 
global phenomena, e.g. body schema remains to be determined since they likely emerge 
from the convergence of primary afferent information with a vast array of other sensory 
information, e.g. vestibular or visual (Driver and Spence 1998; Shimojo and Shams 
2001; Stein 2012).  
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CHAPTER 5. CONCLUSIONS  
Our overall objective was designed to correct the limitations of previous preclinical 
studies to gain understanding of clinically relevant chronic CIPN. Our unbiased 
integrative genomics and protein level studies revealed that clinically relevant 
chemotherapy induced neurotoxicity is codependent and exacerbated by cancer itself. 
Further, we confirm codependence is conserved in the living adult nervous system and 
is expressed as profound neuronal signaling dysfunction. Corrupted signaling 
necessarily impairs the central nervous system of information about body position, 
sensorimotor coordination, and error detection that likely contributes to significant errors 
we discovered in validated measures of sensorimotor behavior in awake behaving 
animals similar to those described by patients. Further, in silico biophysical modeling of 
sensory encoding deficits helped test the sufficiency of our newly identified molecular 
mechanisms of codependent interaction that may act as a novel clinical treatment 
strategy, while deep-learning decoding algorithms afforded the first insights into the 
extent to which sensory encoding errors might compromise information processes by the 
central nervous system. Collectively, our results confirm cancer as a critical feature in 
understanding mechanisms that contribute to neuronal dysfunction caused by 
chemotherapy and have the potential to explain the abject failure of current treatments 
for neuronal dysfunction in cancer treatment. 
While the present report is limited to rats, extensive conservation of core molecular and 
cellular processes across mammalian species (Breschi, Gingeras et al. 2017) leads 
reasonable expectation that cancer-chemotherapy codependency, whether different in 
detail, extends to humans.  All considered, we conclude that inattention to co-
dependencies necessarily prevents the development of mechanism-based treatments 
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for sensory neuropathy, which remains unexplained and unabated in patients receiving 
chemotherapy for cancer. 
Role of the Mechanical Environment in Sensory Encoding Deficits 
While this work focused on developing a deeper understanding and testing specific 
hypotheses surrounding the role of cancer in chronic chemotherapy-induced sensory 
neuropathy, the sensory nervous system’s (and more specifically the mechanosensory 
system studied in this work) inextricable link to the mechanical environment their housed 
in, i.e. muscular system, necessitates discussion of its potential role in our findings. 
Mechanosensory function depends on the transduction of mechanical stimuli, e.g. 
kinetics or kinematics, by receptor endings into trains of action potentials (encoding). 
Any alteration to active or passive properties of muscular system or motor physiology 
has the potential to contribute to encoding deficits. This possibility is plausible since both 
chemotherapy (Sakai, Sagara et al. 2014; Sorensen, Petersen et al. 2017) and cancer 
(Dodson, Baracos et al. 2011; Aoyagi, Terracina et al. 2015; VanderVeen, Hardee et al. 
2017; Schmidt, Rohm et al. 2018) are known to influence muscle homeostasis.   
Cachexia is a well-documented adverse effect of cancer that primarily targets skeletal 
muscle, as opposed to anorexia or starvation which typically affects adipose tissue 
(Porporato 2016). It is associated with severe muscle wasting, reduced physical 
function, reduced tolerance to anticancer therapy, and reduced survival in a variety of 
clinical populations (Tisdale 2002; Fearon, Strasser et al. 2011). Preclinical studies have 
begun to identified specific mechanisms not entirely explained by the muscle atrophy 
(Roberts, Frye et al. 2013) such as: decreased tetanic force, and specific tension, along 
with slowed contraction rates and increases in muscle fatigability (VanderVeen, Hardee 
et al. 2017); Roberts, Frye et al. 2013). These findings are consistent with observations 
of ex vivo muscle preparations extracted from cancer patients, e.g. decreases in 
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stiffness (relative stiffness–pCa2+ relationship) and maximal force production per cross-
sectional area, and a right-shift in Ca2+ activation sensitivity across both MyHC type I 
and IIa (Ochala and Larsson 2008). While we did not observe overt alteration in peak 
muscle contraction force or rate of rise during electrically evoked twitch contractions or 
changes to the force-length relationships during physiologic stimuli, all of the above have 
the potential to contribute to alterations in mechanotransduction that we may not be able 
to detect from our whole muscle measures.  
Chemotherapy also has the potential to influence certain aspects of muscle homeostasis 
(Sakai, Sagara et al. 2014; Sorensen, Petersen et al. 2017). Following oxaliplatin 
treatment histological analysis of pretibial flexors revealed significant leftward shift in the 
fiber size distribution, i.e. smaller cross-sectional area, whereas whole quadriceps 
muscle atrophy could be detected in as little as 5 days of cisplatin treatment (Sakai, 
Sagara et al. 2014). In addition, chemotherapy induces changes consistent with 
myopathy including accumulation of both Ca2+ and lipids along with higher levels of 
collagen deposition present another challenge to canonical muscular architecture that 
could contribute to altered mechanotransduction.  
While the previous discussion, centers on the independent effects of cancer and 
chemotherapy, the present work underscores the potential for combinatorial effects on 
different systems including motor physiology. This becomes credible since some effects 
of chemotherapy overlap those seen in cancer cachexia (Sakai, Sagara et al. 2014; 
Sorensen, Petersen et al. 2017). As an example, recent gene expression data suggest 
that changes in skeletal muscle induced by oxaliplatin may activate similar pathways to 
those activated during cancer cachexia (Feather, Lees et al. 2018). Recent preclinical 
data suggest even more explicit evidence of suspected interaction at a muscular 
systems level (Damrauer, Stadler et al. 2018) which is in agreement with our gross level 
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measure of muscle homeostasis (body weight as an analogue of muscle mass in Figure 
39) that may help clarify some unexplained problems in clinical populations (Vichaya, 
Chiu et al. 2015; Vardy, Dhillon et al. 2016) and paucity of treatment approaches. 
Collectively, these results suggest that both cancer and chemotherapy treatment 
induced pathological changes to the muscular system may contribute to corrupt sensory 
encoding. Notably changes to the mechanical environment may help explain the as yet 
unknown cause of decreases in sensitivity (increases in threshold) for all 
mechanosensitive neurons studied (Aims 3, 4, and 6).  
Figure 39. 
 Longitudinal change in animal weight. Longitudinal study of animal weights reveals systemic non-linear 
interaction of cancer and chemotherapy. a, Weekly weight measures tracking systemic effects of cancer 
and/or chemotherapy. Rats included were used for transcriptional, protein, and physiologic studies. Data are 
mean±s.d. from 15 ApcWT+control, 10 ApcWT+OX, 6 ApcPirc/++control, and 8 ApcPirc/++OX rats.  
Role of the Motoneurons in Decompensated Task Performance  
Despite having strong reason to suspect sensory encoding defects (Aim 3) are 
prominent players in preclinical (Aim 5) and clinical measures of decompensated task 
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performance and patient complaints (see Introduction), we have not established a causal 
link. This leaves the possibility of additional contributors. One prominent candidate is the 
motoneuron, the efferent component of sensorimotor behaviors. We recently identified 
the first evidence that chemotherapy chronically impairs firing behavior of spinal 
motoneurons (Housley, Nardelli et al. 2020 in revision). Data indicate that unstainable 
and unpredictable repetitive firing originates in the motoneurons central integrative 
components, possibly as a result of imbalance in the subthreshold currents that regulate 
firing. 
Their erratic firing necessarily disturbs steady muscle contraction, motor performance 
and might lead to the development of movement disorders experienced by patients 
following chemotherapy (Bennett, Park et al. 2012; Tofthagen, Donovan et al. 2013).  
Specifically, effects on motoneurons could degrade task performance at two level. 
Motoneurons may act directly via altered neuromuscular control and/or indirectly by 
influencing sensory neuron encoding by altering the mechanical environment that 
sensory neurons operate in (discussed above). Direct influence of altered active 
neuromuscular control would be in addition to the potential corruption of intrinsic muscle 
homeostasis (discussed above). While previous reports have observed deficits 
consistent with motoneuron involvement, these studies utilized either indirect measures 
or focused on acute hyper-excitability which in both instances do not necessarily provide 
insight into the lasting signs and symptoms experienced by cancer survivors (Burakgazi, 
Messersmith et al. 2011; Tofthagen, Overcash et al. 2012; Kneis, Wehrle et al. 2016; 
Taleb, Bouzobra et al. 2017).  In any event, motoneuron involvement would work to 
compound any effects induced independently from corrupt sensory encoding.  
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Evidence for Codependency. 
For many studies, particularly those at the clinical level, decoupling chemotherapy-
induced effects and those induced by cancer is difficult. As we have identified, no 
preclinical study has investigated the synergistic effect of the disease and chemotherapy 
for CIPN (Currie, Angel-Scott et al. 2018) with most opting to investigate each in 
isolation. Outside of CIPN, one preclinical study did examine fatigue-related behaviors in 
mice with Lewis Lung Carcinoma cell tumors (Wood, Nail et al. 2006) that received 
Etoposide a topoisomerase II inhibitor and member of the broadly family of alkaloid 
agents. Etoposide significantly reduced voluntary wheel running activity, an index of 
fatigue (Novak, Burghardt et al. 2012), above control with further reductions in activity 
noted in animals with tumors. Human studies only allow us to infer exacerbation of 
symptoms by chemotherapy on existing fatigue in cancer patients. For example, reduced 
muscle strength and function was observed in individuals with acute lymphoblastic 
leukemia diagnosis prior to treatment (Ness, Kaste et al. 2015). Symptoms worsened 
following chemotherapy treatment, which suggests a significant role of chemotherapy in 
the development of these symptoms. A recent large-scale observational study found 
increased fatigue in a cohort of individuals diagnosed with colorectal cancer that 
underwent chemotherapy treatment, as opposed to those that did not (Vardy, Dhillon et 
al. 2016). These few reports highlight the fact that little work has been done to 
investigate and test for the explicit role of interaction effects between cancer and 
chemotherapy in any side-effect of treatment or disease. Coupled with the abject failure 
of current treatment approaches for chronic CIPN, the above discussion underscores the 
importance of our findings and necessitate further study of these non-linear interactions 
and their effects on potential treatments.  
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Mechanisms of Codependency  
We have now firmly established that codependent effects of chemotherapy and cancer 
exist at multiple levels of biological control, e.g. gene and protein expression, control 
neuron excitability, and behavioral performance, and that their interactions significantly 
exacerbate deficits at each level.  We must now move to determine the underlying 
mechanisms (sites) of this interaction. More importantly, with the recognition that neither 
process is stationary with respect to time, e.g. development of cancer, accumulation of 
chemotherapy, and subsequent suppression of cancer, we must uncouple the temporal 
pattern by which these two systemic perturbations work together to influence 
pathophysiology of chronic CIPN (and likely other side effect that remain recalcitrant to 
treatment). Filling this gap in knowledge is needed to expose the most effective 
treatment targets or cures for chronic CIPN (Hershman, Lacchetti et al. 2014). Barriers 
to obtaining this information are formidable, given the overwhelming abundance and 
complexity of possible pathways identified by our multiscale approach. however, given 
the magnitude and multiple scales of dysregulation we observed leads us to suspect that 
codependent interactions may be mediated by high-levels of biological control. Such 
candidates include DNA methylation and hydroxymethylation, histone modification, e.g. 
acetylation and deacetylation and non-coding RNA regulation, e.g. miRNAs, all of which 
comprise global regulatory processes known as epigenetic phenomena. While it is clear 
that perturbation to epigenetic control may lead to alterations in gene expression which 
results in cellular transformation and ultimately cancer development (Lund and van 
Lohuizen 2004; Esteller 2008); it is less clear whether cancer itself can cause alterations 
to epigenetic control either directly or indirectly via systemic signaling pathways 
(inflammatory). Identifying the existence of such reciprocal relationships may be crucial 
to determine where feedback loops intersect with the known influences of chemotherapy 
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on epigenetic control in the nervous system of animals in preclinical study, e.g. increase 
H3 acetylation and decreased histone deacetylase activity (Briones and Woods 2011; 
Wang, Walitt et al. 2015). While the evidence is far from conclusive, we hypothesize that 
the administration of chemotherapy agents in the presence of systemic influence of 
cancer initiates a cascade of biological changes, with transient alterations in low levels of 
biological control, e.g. hyperexcitability: a positive acute effect observed throughout the 
nervous system and changes in inflammatory milieu that ultimately converge on high 
level epigenetic alterations that persist long after treatment cessation and disease free 
survival. These epigenetic changes would then lead to gene expression changes, 
altering metabolic activity and neuronal alterations that are responsible for generating 
clinically relevant chronic CIPN.  Effects of epigenetic alterations may also help explain 
heterogeneity in patient populations. A recent study indicated a strong association 
between the strength of persistent methylation changes and developed persistent 
neuropsychological symptoms, whereas patients with preserved methylation status were 
protected from chronic symptoms (Lyon, Elmore et al. 2014).  
Alternatively, lower levels of biologic control might be the center of codependent 
interactions between cancer and chemotherapy that ultimately result in exacerbated 
chronic neurologic deficits.  Fortunately, our unbiased transcriptional analyses afforded 
some insight into this possibility. Our data point to changes in oxidative, inflammatory, 
and metabolic pathways as likely culprits. While previous studies suggest changes to 
systemic inflammatory milieu are transient (Wang, Walitt et al. 2015), our data point to 
both genetic (Aim 1) and protein (Aim 2) level pathway disruption that persists after 
treatment cessation.  Differences may be attributable to divergence in experimental 
targets. Our preclinical studies afforded unique tissue specific focus on the sensory 
nervous system, while prior work was limited to experimental targets accessible in 
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clinical populations namely minimally invasive sampling from blood. Moreover, the 
expression of persistent changes in low levels of biologic control simply rules in their 
potential role and does not rule out the possibility that they emerge from high-level 
epigenetic alterations that this work cannot currently disentangle.  
In summary, innumerable pathways and/or loci exist that could house interaction. It is 
tempting then to speculate where and when interactions are taking place; however, 
despite definitive evidence that clinically relevant sensory neuropathy is codependent on 
cancer and chemotherapy, it is futile to attempt to constrain possibilities at this time 
because we simply don’t have adequate spatiotemporal resolution across the relevant 
tissue specific domains. That being said, we are hopeful that the trends in big data and 
powerful computational modeling, some of which we developed in this project, will 
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Microarray datasets supporting the conclusions of this article are available in the Gene 
Expression Omnibus (GEO) repository under accession code: GSE126773. Other 
datasets supporting the conclusions of this article are included within the article and its 
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